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CHAPTER I
INTRODUCTION

Glucose homeostasis is normally maintained by a balance
between hepatic glucose production and glucose utilization
by peripheral tissues (fat, muscle, and brain)

(1).

Insulin

and glucagon, which are both secreted from the pancreatic
islets, help to maintain this balance by their actions on
peripheral tissues (primarily muscle, liver, and fat).
Failure of the body to regulate blood glucose levels
properly can lead to a variety of disorders, the most common
of which is diabetes mellitus.
Diabetes mellitus is a heterogeneous disease that is
characterized by hyperglycemia with insulin resistance of
peripheral tissues and a deficiency of adequate insulin
levels to lower blood glucose in the presence of a glucose
challenge (2,3).

There are two main categories of diabetes

which fall under this definition.

The first is Type I or

Insulin-Dependent Diabetes Mellitus (IDDM), a condition
wherein destruction of the pancreatic

~

cells leads to loss

of insulin production and consequent loss of glycemic
control.
(2).

The result is hypoinsulinemia with hyperglycemia

The other category is Type II or Non-Insulin-Dependent
1

2

Diabetes Mellitus (NIDDM), in which patients display
hyperglycemia, insulin resistance of peripheral tissues,
and, in the earlier stages of the disease, hyperinsulinemia
(1,3-9).
In both disorders, peripheral tissues display a
resistance to insulin, although this resistance is
particularly pronounced in NIDDM (2,6).

Insulin initiates

cellular actions by binding to a cell surface receptor, and
recent studies have begun to clarify the first stages of
insulin signaling (10).

Insulin resistance in NIDDM is

thought to result in many cases from a post-receptor defect
in insulin signaling (1,4,8,9,ll,12).

We therefore

evaluated in an animal model of NIDDM the expression and
function of proteins involved in the early signaling events
following insulin binding to its receptor.

We further

examined these parameters following treatment of such
insulin resistant diabetic animals with an antihyperglycemic agent of the thiazolidinedione class known to
lower blood glucose levels by sensitizing cells to insulin
(13-20).

In addition, an animal model of IDDM was similarly

studied to determine if early insulin signaling events are
altered by hyperglycemia in the absence of hyperinsulinemia.
The goal of these studies was to gain a better understanding
of the cause of cellular insulin resistance, as well as to
further understand the corrective action mechanism of a
novel class of compounds with great potential for the

3

treatment of non-insulin-dependent diabetes mellitus.

CHAPTER II
REVIEW OF RELATED LITERATURE

overview
The focus of this project was to study alterations in
early steps of the insulin signaling pathway in insulin
resistant diabetes, and to compare these alterations with
possible defects in insulin deficient diabetes.

Therefore,

both diabetic syndromes will be discussed, followed by an
overview of insulin signal transduction.

Insulin Dependent Diabetes Mellitus CIDDMl

Suspected Causes of IDDM
Five percent of the population of the United States is
afflicted with diabetes mellitus.

Of these individuals,

about 80-85% have NIDDM, and 15-20% have IDDM (21).

IDDM,

like NIDDM, apparently results from a mixture of genetic and
environmental factors (21).
destruction of the pancreatic

The main defect in IDDM is a
~

cells, resulting in a loss

of the ability to produce and secrete insulin (2).
insulin deficit causes two problems.

First, ingested

glucose is not utilized or disposed of by tissues
4

This
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efficiently.

Secondly, insulin deficiency stimulates

glucagon secretion, which stimulates glucose release from
the liver.

Consequently, this results in hyperglycemia,

dehydration, and glycosuria (2).
Although the etiology of IDDM is much more clear than
the cause of NIDDM, there is some controversy concerning the
primary origin of the disease.

This is probably due to the

fact that although there is a genetic predisposition to
IDDM, environmental factors play a substantial role (22,23).
In fact, although the incidence of IDDM is greater in
relatives of IDDM patients (5-6%) than in the general
population (0.3-0.5%), the concordance rate between
identical twins is only about 34% (22).

The one point that

is agreed upon is that the cause of islet cell destruction
is an autoimmune response targeted at

the~

cells (22,24).

Genetic Factors Leading to IDDM
One of the strongest genetic indicators of IDDM is
found in the Human Leukocyte Antigen (HLA) system of the
Major Histocompatibility Complex (MHC) class II proteins.
These are the proteins expressed on the surface of cells, in
this case pancreatic

~

cells, which are responsible for

recognition of "self" by the immune system (22,23).

There

are two main HLA markers which are associated with a
predisposition to susceptibility to IDDM.

The first is that

DR3/DR4 heterozygotes have a 46-fold increased risk of

6

developing IDDM (22,23).

The second is that a mutated

DQ~

chain with an amino acid other than aspartate at position 57
has an even stronger link with the incidence of IDDM
(22,23).

Although there is no direct association between

the function of these proteins and the cause of IDDM, these
genotypes have been found to be more susceptible to
infection with Coxsackie B virus (23).

Also, these MHC

proteins may be involved in autoimmunity caused by early
exposure to milk proteins, which is discussed below.
Another genetic cause of type I diabetes involves
antibodies to islet cell-specific antigens.

Among the

proteins found to cross-react with islet cell antibodies
found in IDDM patients are glutamic acid decarboxylase
(GAD), insulin, proinsulin, heat shock protein 65,
carboxypeptidase H (an enzyme involved in the conversion of
proinsulin to insulin), and glucose transporter GLUT-2
(23,25-27).

Antibodies to GAD have been found in 80% of

recent onset type I diabetics (26).

Environmental Factors Leading to !DOM
Because the concordance rate of IDDM in monozygotic
twins is only about 34%, environmental influences may also
play a role in the development of IDDM.

Environmental

factors involved in the development of type I diabetes are
stress, nitrosamines from smoked meat, seasonal variation,
high nitrates, coffee, sugar, high latitude, low average

7

temperature, exposure to certain insecticides, and exposure
to solid foods before three months of age (24,28).

However,

the two most likely environmental influences are viral
infection and early exposure to cow's milk (23,24,28-30).

Viral influences.

Evidence for the involvement of

viruses in IDDM centers on the presence of Coxsackie B virus
in newly diagnosed IDDM patients, a strong correlation of
maternal rubella infection during pregnancy and IDDM of the
offspring, and the fact that Coxsackie BJ, Coxsackie B4, and
retrovirus type 3 viruses can all infect human

~

cells in

culture (29,30). In addition, SJL/J mice infected with
Coxsackie B virus, Mengovirus, and Encephalomyocarditis
(EMC) virus all developed IDDM (29).

There is also a strong

correlation between the Cytomegalovirus (CMV) genome and
islet cell antibodies found in IDDM patients (23).
not known whether the viruses necessarily infect the

It is
~

cells

themselves or if the viral-induced destruction of these
cells are a result of antibodies directed against viral
antigens cross-reacting with islet antigens.

Milk proteins.

Recent studies have shown that early

exposure to cow's milk could contribute to the development
of IDDM, and that breast-feeding of infants could have
protective properties against this disorder (23,24,30).

8

In newly diagnosed diabetic children and in spontaneously
diabetic rats fed cow's milk, antibodies to bovine serum
albumin {BSA) and
(30).

~-lactoglobulin

were found in high levels

Anti-BSA antibodies have been found to recognize an
~

islet-specific plasma membrane protein of
as islet cell antibody 69 (ICA69)

(24,30).

69,000, known
Also, BSA shares

a region of homology with the MHC class II proteins Ia, DQ,
and DR (30).

Interestingly, the region of homology between

BSA and

DQ~

above.

Further, the difference between human and bovine

includes the position 57 amino acid discussed

serum albumin is that the human serum albumin has an
aspartate in the region of homology with

DQ~

corresponding

to amino acid number 57, while BSA has an alanine.
Therefore, this could partially explain an increased
incidence of IDDM in patients with an amino acid other than
apartate at position 57 of the

DQ~

MHC protein {30).

There is much controversy concerning all of these
possible causes, mainly because individuals with any of
these predisposing factors do not necessarily develop IDDM
{24).

Because of this, IDDM is thought to be a

multifactorial disease of heterogeneous origin.

Treatment of IDDM
The most widely used treatment for type I diabetes is
the administration of exogenous insulin and tight dietary
control (2).

9

Non-Insulin-Dependent Diabetes Mellitus CNIDDM)

The cause and Progression of NIDDM
Insulin resistant or non-insulin dependent diabetes
mellitus is a condition of unknown etiology which is
associated with insulin resistance of peripheral tissues,
hepatic glucose overproduction, and impaired
(1,3-6,8,9,31-34).

~

cell function

The result of these anomalies is

hyperglycemia, hyperlipidemia and hyperinsulinemia in the
earlier stages, followed by hypoinsulinemia in the later
stages when overt NIDDM ensues {l,3,4,34).
This condition is precipitated by both genetic and
environmental factors {l,6-9,33,34).

Unknown genetic

factors initiate the development of diabetes, resulting in
altered expression of diabetes-related genes.

These

alterations are exacerbated by diet and obesity to bring
about insulin resistance and eventually overt diabetes
{l,6,33,34).

Although there is some controversy as to whether
insulin resistance or pancreatic

~

cell dysfunction is the

primary genetic defect causing diabetes, there is
considerable evidence suggesting that insulin resistance
occurs

before~

cell dysfunction (1,6).

One of the best

arguments for insulin resistance preceeding a

~

cell defect

is that in the early stages of NIDDM, patients exhibit
hyperinsulinemia and resistance to exogenously supplied

10

insulin or endogenously secreted insulin (1,6).

One of the

earliest detectable defects in first-degree relatives of
NIDDM patients is impaired insulin action in muscle and
adipose tissues (21).

In studies where individuals with a

family history of NIDDM were followed longitudinally,
insulin resistance appeared to be present for many years
before the clinical onset of the disease (1).

However,

given the probable polygenic inheritance of the disease, it
is possible that either a defect in
both insulin resistance and

P cell

P

cell function alone or

defects are contributing

factors in some cases (6).
In addition to these genetic factors, other
contributing factors are obesity and dietary conditions.

In

particular, increased abdominal obesity is associated with
insulin resistance and increases the risk of developing
NIDDM (1).

Also, in offspring of diabetic parents, insulin

resistance was found to increase as body weight increased
(35).

Thirdly, KK mice, which show glucose intolerance and

insulin resistance but not hyperglycemia when fed laboratory
chow, developed hyperglycemia and glycosuria when fed a diet
that induced obesity (36).

KKAY Mice as a Model of NIDDM
The Upjohn colony of KKAY mice was originally obtained
from Takeda Chemical Industries in Osaka, Japan.

The KKAY

mouse strain was established as a model of obese type II
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diabetes for the purpose of screening antihyperglycemic
compounds (37).

The colony is maintained by crossing obese

insulin-resistant yellow KKAY males with glucose intolerant
KK females (37).

KKAY mice originally were the result of a

cross between albino KK mice and yellow obese mice (AY)
(36).

KK mice are an inbred strain with a diabetic

phenotype consisting of impaired glucose tolerance, moderate
hyperglycemia, insulin resistance of peripheral tissue, and
hyperinsulinemia (36).

The AY gene causes mice to become

obese and also causes a yellow coat pigmentation of the
animals carrying this gene (36).

The offspring from the KK

x AY cross consisted of four groups: yellow KK mice or KKAY
mice (AYa, BB, Cc); albino KKAY mice (AYa, BB, cc); black KK
mice (aa, BB, Cc); and albino KK mice (aa, BB, cc)

(36).

Therefore, the yellow offspring from the KK x AY cross
possess the diabetic features of the KK mice as well as the
obesity trait of the AY parent (36) .
KKAY mice have significantly higher body weight, fat
pad size, blood glucose and plasma insulin levels than
nondiabetic C57Bl/6 control mice (37).

In contrast to the

elevated plasma insulin levels, KKAY mice have only a very
small amount of pancreatic insulin as compared to C57 mice,
suggesting that the islet cells are under considerable
stress to secrete more insulin to meet the demand of the
insulin-resistant tissues (37).

KKAY mice also have a

higher basal glucose uptake than C57 mice and are insulin-

12
resistant as assayed by insulin-stimulated glucose transport
into isolated adipocyte cells (18).

Because of these

observed phenotypic similarities with NIDDM, KKAY mice are
considered an attractive model for studying obesity-linked
type II diabetes (37).
The only drawback to the KKAY model of insulinresistant diabetes is that since both parental strains
possess diabetes-related characteristics, there is no
genetically-related control mouse strain.

C57Bl/6J mice

have been used as controls in past studies with KKAY mice
because in comparison with KKAY mice, C57Bl/6J mice diplay
normal glucose, insulin, and triglyceride levels, and are
insulin-sensitive (18,19,37).

Treatments for NIDDM

Past Treatments
Regardless of the precipitating cause of NIDDM, the end
result in overt diabetes is hyperglycemia and inadequate
insulin secretion.

To correct this condition, treatments

for NIDDM patients have focused on increasing insulin output
from the pancreas by oral administration of insulin
secretagogues (11), and also by increasing exercise and by
altering diet for desired weight loss to reverse insulin
resistance (4,11,34).

13
Future Treatments
A recent development in the treatment of NIDDM has been
the discovery of a new class of compounds that acts to
sensitize tissues to insulin rather than increasing the
secretion of insulin.

These compounds, the

thiazolidinediones, increase insulin sensitivity in Wistar
fatty rats as well as obese insulin resistant KKAY mice
(13-15,17,18,20).

In addition, triglyceride levels,

nonesterified fatty acids, and cholesterol levels were also
lowered in the treated animals (15,38).

The mechanism of

action of thiazolidinediones is unknown, but several studies
have shown that they work by increasing glucose uptake
(18,20), altering gene expression (17-19,39-41), and
enhancing insulin receptor kinase activity (16,42-44)
without increasing insulin binding.

Incubation of Rat-1

fibroblasts with the thiazolidinedione troglitazone (CS045)
reversed the inhibitory effect of high glucose on insulinstimulated tyrosine phosphorylation of the insulin receptor
and the insulin receptor substrate-1 (IRS-1)

(42).

Also,

epididymal fat pads from diabetic ob/ob mice pretreated with
the thiazolidinedione ciglitazone showed an increase in
insulin-stimulated glucose oxidation and lipogenesis as
compared to untreated diabetic mice (45).

The

thiazolidinediones are presently in clinical trials (46).
One compound of this class, pioglitazone, was used in our
study in order to determine if it elicited its effects at
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the level of insulin signal transduction.
studies by Sizer, et al.

Two recent

(47) and Zhang, et al.

(48) suggest

that pioglitazone may act by directly augmenting early steps
of signal transduction, specifically activation of
phosphatidylinositol 3'-kinase.

Signal Transduction
Upon reaching its target cells (primarily muscle,
liver, and adipose), insulin transmits its signal to the
cell interior by binding to its receptor on the plasma
membrane.

The binding of insulin initiates an intracellular

signaling cascade which distributes insulin's signal to the
rest of the cell, activating insulin-dependent processes
such as glucose uptake, glycolysis, glycogen synthesis,
amino acid uptake, and DNA synthesis.

Insulin resistance of

peripheral tissues is due to an attenuation of insulin's
signaling system or a defect in one or more of the processes
of glucose metabolism.

Due to the recent elucidation of the

first steps of insulin action, it is the beginning of the
signaling cascade which has been the focus of this study.
Therefore, the components involved in the first stage of
insulin signaling will be discussed.

15
The Insulin Receptor

Structure
The insulin receptor is a heterotetrameric structure
composed of two a and two B subunits linked by disulfide
bonds to yield an a 2B2 receptor (49-53).

The two a subunits

are extracellular glycoproteins, each of MW 135,000, and are
responsible for the binding of insulin (4,54).

The two B

subunits are 95,000 MW transmembrane glycoproteins which
contain ATP binding sites and the tyrosine kinase activity
of the receptor (49-51,53-55).

Each aB dimer is encoded by

a gene of 22 exons located on human chromosome 19.

The

proreceptor, translated from a single mRNA, is either a 1343
or 1355 amino acid protein depending on alternative splicing
of exon 11, plus an additional 27 amino acid signal peptide
at the NH2-terminal end (56).

The two forms of the insulin

receptor generated by alternative splicing of exon 11 (in
the a subunit) are believed to have different properties.
The A form, without exon 11, has a higher affinity for
insulin (57).

The B form, with exon 11, has a lower

affinity for insulin (higher Km), but has an 8-fold higher
Vmax and shows a two-fold higher insulin-stimulation of
phosphotyrosine in the insulin receptor
synthetic substrate (57,58).

P subunit

and a

In addition to the splicing of

exon 11 in the mRNA from which the protein is translated,
alternate poly-A site selection results in two different-

16
sized transcripts, 9.5 and 7.5 kb.

This poly-A site

selection does not have a known role in the expression of
the insulin receptor (59).
As the receptor protein is processed, the signal
peptide is cleaved and the proreceptor is glycosylated.

Two

of these proreceptors are then joined by disulfide bonds
within the regions corresponding to the a subunits, and then
another cleavage event cuts each proreceptor into a and B
subunits.

The a and B subunits are also joined by disulfide

bonds, and thus the mature insulin receptor is an a 2B2
heterotetramer held together by disulfide bonds (56).

Receptor Activation
Once insulin binds to the a subunit, the receptor
undergoes a conformational change that results in a series
of intramolecular tyrosine autophosphorylation events and
subsequent activation of the B subunit tyrosine kinase
activity toward exogenous substrates (49,51,54,56).
Autophosphorylation experiments carried out at 0°C suggest
that tyrosine 1146 is the first residue to be phosphorylated
in the B subunit, followed by phosphorylation of tyrosine
1150 or 1151.

This region is considered a regulatory region

of the B subunit, since all three of these tyrosines must be
phosphorylated in order to fully stimulate the
phosphotransferase activity of the insulin receptor toward
its exogenous cellular substrates (51).

All of these

17

tyrosine phosphorylation events seem to require lysine at
position 1018, which is positioned in a potential ATP
binding site.

Mutation of this residue to alanine,

arginine, or methionine inactivated the receptor kinase
activity (56,60).
Once the B subunit is tris-phosphorylated in this
region, it is further phosphorylated at tyrosine residues
1316 and 1322. Phosphorylation of tyrosines 1316 and 1322
does not seem to be required for activation of the B subunit
phosphotransferase (61), although this carboxy-terminal
region may play a role in regulating insulin's growthpromoting effects (62).

Studies by Kaliman, et al. and

Pang, et al. have shown that this c-terminal domain of the
receptor may be involved in negatively regulating the
insulin receptor kinase (63,64); however, other work has
shown that deletion of the c-terminus of the

~

subunit

actually caused a decrease in insulin-stimulated receptor
autophosphorylation and receptor internalization without
changing insulin-stimulated IRS-1 phoshorylation,
phosphitidylinositol 3'-kinase activity, glucose uptake, or
DNA synthesis (65).

In contrast to this study, Smith et al.

found that the c-terminus of the receptor was not important
in receptor internalization (66).
Another important region of the insulin receptor
subunit is the juxtamembrane domain.

~

Mutation of tyrosine

960 to phenylalanine impaired the insulin-stimulated

18
phosphorylation of the main insulin receptor substrate, IRS1, as well as the activation of phosphatidylinositol 3'kinase and microtubule-associated protein kinase (MAPK)
(67).

Mutation of aspartate 938 to valine caused the

tyrosine kinase of the receptor to be activated in the
absence of insulin (68).

The amino acids between positions

954 and 965 in this region of the receptor are also involved
in insulin-stimulated receptor internalization (67).
Other important functional domains of the receptor
include serine/threonine phosphorylation sites and
glycosylation sites.

The insulin receptor is known to be

phosphorylated on serine and threonine residues after
insulin stimulation (69-73), and there is some evidence for
this phosphorylation inhibiting the insulin receptor kinase
(69,70).

Several studies involving mutation of serines 967,

974, 976 and threonine 1336 showed that these sites are not
important in insulin receptor function (72,73).

In

addition, elimination of serine phosphorylation of the
juxtamembrane domain had no effect on insulin receptor
autophosphorylation (71).

Unlike the serine/threonine

phosphorylation, glycosylation of the receptor is very
important in receptor function.

Mutation of the

glycosylation sites of the a subunit caused the insulin
receptor to be retained in the endoplasmic reticulum in the
proreceptor form, while the

~

subunit glycosylation sites

were found to be required for signal transduction (74).

19
Insulin Receptor Defects

Alternative splicing of exon 11.

Recent evidence

suggests that alternative splicing of exon 11 of the insulin
receptor may play a role in the development of NIDDM,
although this has been controversial.

Some data has shown

that there is a higher ratio of the B form of the receptor
(with exon 11), which has a lower affinity for insulin, in
NIDDM patients as compared to nondiabetic controls
(57,75-77).

However, there are also reports of equal ratios

of A and B forms between control and NIDDM patients (78,79),
and also some reports of a higher ratio of the A form in
NIDDM as compared to nondiabetic controls (80,81).

It is

difficult to rationalize the differences between these
studies, but one explanation may be that different NIDDM
groups have different ratios, or possibly that there is not
an absolute correlation between splicing products of the
insulin receptor and NIDDM.

Other mutations.

There are several documented

mutations of the insulin receptor leading to insulin
resistance, and such mutations reportedly affect the insulin
receptor at different points in its synthesis, processing,
binding, function, and internalization (82).

The most

severe forms of NIDDM, such as Rabson-Mendenhall syndrome
and leprechaunism, were associated with mutations in the a

20
and~

subunits of the insulin receptor (83).

However, these

collective mutations only account for the insulin resistance
of 1-10% of all NIDDM patients, and thus there are probably
some other defects which cause insulin resistance in the
majority of NIDDM patients (3,12,82,83).

These other

defects are likely to occur in intermediate steps of the
insulin signaling pathway.

The Insulin Receptor Substrate-1 (IRS-1)

Structure of IRS-1
As mentioned above, insulin binding to its receptor
activates the tyrosine kinase activity of the receptor
toward intracellular substrates.

The main protein

identified to be tyrosine phosphorylated upon insulin
stimulation migrates between 160 and 185 kDa on SDSpolyacrylamide gel electrophoresis (84-87).

This protein

has been cloned and sequenced by two separate groups from
Fao hepatoma cells and 3T3-Ll adipocytes, and has been named
insulin receptor substrate-! (IRS-1)

(85-88).

Although IRS-

1 migrates as a larger protein on SOS-PAGE, it is a 131,000
MW hydrophilic protein, translated from a 9.5 kb mRNA.

The

difference in mobility and molecular weight is thought to be
due to the high basal serine phorphorylation and high

~

sheet content of IRS-1 causing the protein to migrate as a
larger protein (85,89).

Although it contains a putative ATP
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binding site (gly1n-val-gly-glu-ala-gly- ... -lys~ 6 -X-ile), it
lacks the asp-phe-gly or ala-pro-glu sequences diagnostic of
a protein kinase (85).
Before insulin stimulation, IRS-1 exists as a
phosphoprotein containing phosphoserine and some
phosphothreonine but no phosphotyrosine.

IRS-1 contains 35

serine/threonine phosphorylation sites, and at least 20
potential tyrosine phosphorylation sites (85,90).

There is

some evidence for an increase in serine/threonine
phosphorylation on insulin stimulation (89,90), which could
inhibit tyrosine phosphorylation of IRS-1 or inhibit the
docking of other proteins to the activated IRS-1 {89,90).
However, the majority of insulin stimulated phosphorylation
of IRS-1 occurs on tyrosine residues, and this has been
shown to activate it as a multisite docking protein {10,91).

Tyrosine Phosphorylation and Function of IRS-1
There are several lines of evidence which indicate that
IRS-1 is involved in insulin signaling.
the IR

~

First, aside from

subunit, IRS-1 is the major protein phosphorylated

on tyrosine residues after insulin stimulation
(55,84,86,92,93).

Second, phosphorylation of IRS-1 occurs

within the same time frame and with similar insulin
concentrations as phosphorylation of the insulin receptor B
subunit (55,92).

In fact, maximal phosphorylation of IRS-1

in response to insulin occurs within 30 seconds, which
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directly correlates with phosphorylation of the insulin
receptor.

This implicates IRS-1 as a direct substrate of

the insulin receptor tyrosine kinase, since no other
phosphorylated products are seen earlier.

Third, an insulin

receptor mutated at tyrosine 960 of the juxtamembrane region
and transf ected into CHO cells was unable to phosphorylate
IRS-1 in response to insulin stimulation, nor was this
receptor capable of mediating normal cellular responses to
insulin such as stimulation of glycogen synthase, amino acid
uptake, or thymidine uptake into DNA, even though this
receptor was still able to phosphorylate itself and other
exogenous substrates (50).

Likewise, mutation of the ATP

binding site lysine-1018 prevented insulin receptor
autophosphorylation and IRS-1 phosphorylation in the
presence of insulin (60).

Also, cells expressing receptors

with a mutation of tyr-1146 to phenylalanine had impaired B
subunit autophosphorylation as well as impaired IRS-1
phosphorylation (94).
IRS-1 function has been linked to both the metabolic
(95-102) and mitogenic (90,97,103-107) actions of insulin.
An example of the mitogenic involvement of IRS-1 in insulin
signaling is shown in studies with Chinese hamster ovary
(CHO) cells.

Expression of IRS-1 in CHO cells doubles the

maximal amount of thymidine incorporation into DNA
stimulated by insulin, and expression of IRS-1 antisense RNA
in CHO cells reduced the mitogenic response to insulin
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(89,108).

Similarly, Xenopus oocytes, which have very

little or no IRS-1 and which normally do not mature in
response to insulin or IGF-1, were found to mature in
response to insulin and IGF-1 when IRS-1 was transfected
into these cells {106).

Other data showed that disruption

of IRS-1 gene expression in transgenic mice caused a
decrease in intrauterine and postnatal growth by more than
50% (90,109,110).

The strongest evidence supporting a role

for IRS-1 in the metabolic effects of insulin comes from the
association of IRS-1 with phosphatidylinositol 3'-kinase.
IRS-1 has been shown to associate with and activate
phosphatidylinositol 3'-kinase on insulin stimulation
{111-115).

The catalytic activity of phosphatidylinositol

3'-kinase can be specifically inhibited by a fungal toxin,
wortmannin, and this action results in inhibition of
insulin-stimulated glucose uptake (95,96,99,102), thus
linking IRS-1 and PI3K with a well-known metabolic response
to insulin.
As mentioned above, once IRS-1 becomes tyrosine
phosphorylated by the insulin receptor kinase, it acts as a
multisite docking protein via an interaction of its
phosphotyrosine residues with src-homology 2 {SH2) domains
of several target proteins {10).

SH2-containing proteins

that interact with IRS-1 on insulin stimulation include the
p85a subunit of phosphatidylinositol 3'-kinase (PI3K), the
tyrosine phosphatase Syp/SH-PTP2/PTP1D, growth factor
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receptor bound protein 2 (GRB2), and Nck (10,91,116-120).
schematic diagram of this is shown in fig. 1, adapted from
White and Khan, 1994 (10).

The specificity of these

interactions is determined by the sequences surrounding

Glucose
Transport

Fig. 1. Early steps in insulin signal transduction.

A
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the phosphorylated tyrosines (pY) of IRS-1 and the sequence
of each SH2 domain on the target proteins.

The p85a subunit

of PI3K prefers pYMXM motifs (phosphotyrosine-methionine-any
amino acid-methionine), specifically pY608 and pY939 of IRS1 (91).

GRB2 binds to pY(895)VNI (phosphotyrosine-valine-

asparagine-isoleucine)

(91), while Nck binds most strongly

to pY(147)DTG (phosphotyrosine-aspartate-threonine-glycine)
(118).

Syp has two SH2 domains that bind to pY(1172)IDL

(phosphotyrosine-isoleucine-aspartate-leucine) and
pY(1222)ASI (phophotyrosine-alanine-serine-isoleucine),
respectively (121).

Mutations in IRS-1
When the incidence of amino acid mutations in the IRS-1
gene was compared between NIDDM patients and nondiabetic
control subjects, two mutations were found: a glycine to
arginine transition at position 972 and an alanine to
proline transition at amino acid 513 (122).

Of the 86 NIDDM

patients and 76 normoglycemic controls studied, ten NIDDM
patients and 3 controls were heterozygous for the position
972 polymorphism, while 6 NIDDM patients and 2 controls were
heterozygous for the position 513 polymorphism.

There were

no homozygotes or double heterozygotes with both
polymorphisms.

Another study of French NIDDM families found

that these same polymorphisms did not cosegregate with
diabetes (123).

A different study compared tandem repeat
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mutations in the IRS-1 gene between Japanese NIDDM families
and controls, and found that tandem repeat polymorphisms
were not associated with a higher risk of NIDDM (124).
Therefore, no direct link exists between these naturally
occurring IRS-1 mutations and NIDDM.

Proteins which Associate with Phosphorylated IRS-1

Phosphatidylinositol 3'-Kinase (PI3K)
The phosphatidylinositol 3'-kinase (PI3K) is composed
of an 85 kDa adaptor subunit and a 110 kDa catalytic subunit
(52,125-128).

The 110 kDa subunit is a 1068 amino acid

protein which is related to Vps34p, a Saccharomyces

cerevisiae protein involved in the sorting of proteins to
the vacuole {127).

It catalyzes the phosphorylation of the

D-3 position of the inositol ring of phosphatidylinositol 4phosphate and phosphatidylinositol 4,5-bisphosphate (52,125,
126).

This reaction would yield phosphatidylinositol 3,4-

bisphosphate and phosphatidylinositol 3,4,5 trisphosphate,
respectively.

The biological function of these products is

unknown, but as mentioned above, inhibition of the pllO
catalytic activity with the fungal toxin wortmannin
inhibited insulin-stimulated glucose uptake by blocking
recruitment of vesicles containing GLUT4 transporter
proteins to the plasma membrane via an unknown mechanism
(95,96,99,102,129).

The phosphatidylinositol 3'-phosphate
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products of PI3K action are not cleaved by phospholipase c,
but they have been shown to activate the

r, o,

~'

and

€

isoforms of protein kinase c (130,131).
PI3K may also be involved in insulin-stimulated
mitogenesis (106,107).

The stimulation of Xenopus laevis

oocyte maturation by IGF-I or insulin requires the presence
of IRS-1 and the activation of PI3K through its association
with IRS-1 (106).

Also, microinjection of N- or c-terminal

SH2 domains of p85a into rat-1 fibroblasts stably
transfected with human insulin receptors inhibited insulinstimulated DNA synthesis (107).

Likewise, microinjection of

pYMXM or pYXXM phosphonopeptides into the same cell line
inhibited DNA sythesis from 61-68% as compared to control
cells (107).
The pllO subunit requires the p85a subunit in order to
function (127).

The p85a subunit contains 2 SH2 domains and

1 SH3 domain (85,94,125,132), and may be phosphorylated on
insulin stimulation, although this is controversial (85,94,
100,114,125,133).

There is an overwhelming amount of data

showing that the p85a subunit of PI3K associates with
tyrosine-phosphorylated IRS-1 on insulin stimulation, and
that this association causes PI3K activation (10,91,100,102,
106,111-113,115,119,134-137).

Strong evidence in favor of

the importance of the association of IRS-1 with p85a in PI3K
activation involves the use of synthetic peptides.

In vitro

activation of immunopurified PI3K by recombinant IRS-1 was
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inhibited by the addition of bacterial fusion proteins
containing the SH2 domains of p85a {100,119).

Likewise,

addition of phosphorylated pYMXM motifs from IRS-1 activated
PI3K in vitro {100,112,119).

In addition to these data,

PI3K activity was found in anti-IRS-1 immunoprecipitations
from insulin stimulated cells of a variety of types
{10,101,111,126,135,136,138,139).

Growth Factor Receptor Bound Protein-2 CGRB2)
Growth factor receptor bound protein-2 {GRB2) is a 24
kDa protein containing one SH2 domain flanked by two SH3
domains, and has no known catalytic function of its own
{140).

As mentioned above, GRB2 associates with IRS-1 on

insulin stimulation through its SH2 domains and the
pY{895)VNI motif of IRS-1 {10,91,120,141,142).
GRB2 also associates with another protein, She, on
insulin stimulation {10,105,116,141-145).

She, or src-

homology/collagen protein, has one SH2 domain and a
glycine/proline rich stretch which is homologous to
collagen.

It has no SH3 domain and no catalytic function of

its own (145).

She is also tyrosine phosphorylated on

insulin stimulation by the insulin receptor kinase, and it
is the tyrosine-phosphorylated form of She which binds the
SH2 domain of GRB2 {143,145).

This is shown in fig. 1.

The function of GRB2 lies in its ability to bind to
other proteins.

The N- and c-terminal SH3 domains bind to a
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proline-rich stretch in the c-terminus of the guanine
nucleotide exchange factor son of sevenless {SOS)

sos

(144,146).

then activates ras, which binds the serine/threonine

kinase raf-1 {10).

Raf-1 is then activated to phosphorylate

MAP kinase kinase, leading to activation of MAP kinase
{10,105,116,140,144,146-148) and DNA synthesis {10,116,141,
148).

Another consequence of increased activation of ras or

raf-1 is the increased expression and activity of the
glucose transporter GLUTl but not GLUT4.

This results in

increased basal glucose uptake regardless of insulin levels
{149-151).

The SH3 domains of GRB2 are also responsible for

localization of GRB2 to membrane ruffles {152).

Recent

evidence has shown that a substrate of MAP kinase, PHAS-I,
is involved in insulin activation of translation initiation
{153), suggesting yet another downstream effect of insulin
signaling through GRB2 and ras or raf-1.
A third function of the SH3 domains of GRB2 is to
associate with the proline-rich stretch of the GTPase
protein dynamin.

GRB2 associates with dynamin in

unstimulated cells, and this complex then associates with
phosphorylated IRS-1 on insulin stimulation via the SH2
domain of GRB2 {140,154).

Association of the GRB2-dynamin

complex with phosphorylated IRS-1 or phosphopeptides
containing the sequence of IRS-1 which binds to the GRB2 SH2
domain activated the GTPase activity of dynamin (154).
significance of this complex in insulin signaling is

The
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unknown, but dynamin may be involved in the pinching off of
coated vesicles from the plasma membrane for endocytosis,
and thus it could possibly be involved in receptor
internalization {154).

Transfection of mammalian cells with

mutant dynamin blocked receptor-mediated endocytosis (154).

Another protein found to associate with IRS-1 on
insulin stimulation is Nck, a 47 kDa protein composed almost
entirely of one SH2 and three SH3 domains (155).

The

function of Nck is unknown, but it may bind to a protein
with serine/threonine kinase activity via its SH3 domains
{156), and overexpression of Nck causes cell transformation
and cell proliferation (155,157).

Syp/PTP1D/SH-PTP2
Syp is a 65-72 kDa protein tyrosine phosphatase with
two SH2 domains in its N-terminus, and differs from the
other IRS-1 binding proteins in that it has a wellcharacterized catalytic domain {117).

It has also been

called PTPlD or SH-PTP2 by separate groups.

Syp has been

shown to bind to tyrosine-phosphorylated IRS-1 {91,117), and
incubation with IRS-1 phosphopeptides caused up to a 50-fold
stimulation of the phosphotyrosine phosphatase activity of
Syp in vitro {121).

Syp also binds to and is tyrosine-

phosphorylated by the insulin receptor in vitro on insulin
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stimulation (158-160).

Recent studies have provided

evidence indicating that syp is linked to insulin, IGF-1, or
EGF stimulation of DNA synthesis.

Xiao, et al. showed that

in rat-1 fibroblasts stably expressing the insulin receptor,
insulin~stimulated

DNA synthesis was inhibited by

microinjection of anti-Syp antibodies, phosphonopeptides
containing the IRS-1 phosphotyrosine binding sites for Syp
SH2 domains, or Syp SH2-GST fusion proteins by 60-90%, 5060%, and 90%, respectively (161).

Similar inhibition of DNA

synthesis was seen with IGF-I and EGF stimulation of these
cells under the same conditions, although serum-stimulated
DNA synthesis was not affected by these inhibitors (161).
Therefore, there are factors in serum other than insulin,
IGF-I, or EGF that stimulate DNA synthesis independently of
Syp.

Hypothesis and Specific Aims
Because NIDDM is associated with a variety of metabolic
derangements (2-5,120), and because the cause of insulin
resistance probably lies in a post-receptor defect in most
cases, this project focused on studying early insulin
signaling events as possible sites of defects leading to
insulin resistance and NIDDM.

The rationale for our

hypothesis is that early defects would lead to a greater
variety of derangements downstream, before insulin's signal
branched off to elicit its many different effects.

Such a
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rationale is supported by the observation that two rare but
very severe forms of NIDDM, leprechaunism and RabsonMendenhall syndrome, result from defects in insulin's
initial signaling events; i.e., receptor binding and
autophosphorylation {83).

Hypothesis
The overall hypothesis of this dissertation is that a
primary defect in insulin resistance is an altered
expression or function of an early insulin signaling
component, and that this defect is corrected or compensated
for by the antihyperglycemic agent pioglitazone.

Specific Aims
To test this hypothesis, two models of insulin
resistant diabetes were used.

The insulin resistant KKAY

mice were used as an animal model for insulin resistant
diabetes because such mice are obese, glucose intolerant,
and exhibit hyperglycemia and hyperinsulinemia {36).
Differentiated 3T3-Ll adipocytes pre-fed with high glucose
and high insulin concentrations were used as an in vitro
model of insulin resistance.

In addition, rats made insulin

deficient with streptozotocin treatment were studied to
determine the effect of hyperglycemia in the absence of
hyperinsulinemia on early insulin signal transduction
events.
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Specific Aim 1
To determine if the expression of the insulin receptor,
IRS-1, PI3K p85a, GRB2, Nck, or Syp is altered in liver and
fat tissues of KKAY mice as compared to control nondiabetic
mice.

Protein levels.

First, the protein levels of these

insulin signaling components were compared between KKAY
diabetic mice and control diabetic mice.

mRNA levels.

When the protein levels were found to be

altered between diabetic and nondiabetic animals, the mRNA
levels were examined to determine if the alteration was a
result of a difference in the abundance of the mRNA for
these genes.

Specific Aim 2
To determine if the insulin-stimulated tyrosine
phosphorylation of the insulin receptor or IRS-1 is
defective in KKAY mice as compared to nondiabetic control
mice.

Isolated epididymal adipocytes.

The acute insulin-

stimulated tyrosine phosphorylation of the insulin receptor
and IRS-1 was examined in isolated epididymal adipocytes
from KKAY and control mice by immunoblotting cell extracts
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with anti-phosphotyrosine antibodies.

Specific Aim 3
To determine if the insulin-stimulated association of
IRS-1 to PI3K p85a is defective in KKAY mice as compared to
nondiabetic mice.

Isolated epididymal adipocytes.

Cell extracts from

isolated epididymal adipocytes were acutely stimulated with
insulin, immunoprecipitated for IRS-1, and immunoblotted for
PI3K p85a.

Specific Aim 4
To determine if any of the alterations observed in aims
1-3 were corrected by treatment of animals with the insulinsensitizing agent pioglitazone.

Pioglitazone treatment of KKAY mice.

A third group was

included in the studies in aims 1-3 which consisted of KKAY
mice treated with pioglitazone.

Because the cellular

mechanism of pioglitazone action is unknown, the purpose of
this aim was to determine if pioglitazone treatment affected
early insulin signaling events.

Specific Aim 5
To determine if the alterations observed above in KKAY
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mice were due to the high levels of insulin and glucose
associated with the diabetic condition.

High glucose and high insulin.

Differentiated 3T3-Ll

adipocyte cell cultures were treated overnight with medium
containing high levels of glucose and insulin, thus
representing the hyperglycemic and hyperinsulinemic state
seen in the diabetic KKAY mice.

The expression of early

insulin signaling components in this model was compared to
the expression of these factors in control cells pre-fed for
the same time interval with low glucose and low insulin
levels.

In addition, the ability of insulin to stimulate

receptor autophosphorylation and IRS-1 phosphorylation was
also analyzed in this model.

High glucose.

To determine if any alterations observed

in insulin-resistant mice were due to high blood glucose
levels, the expression of these insulin signaling mediators
was studied in rats made insulin-deficient by streptozotocin
treatment.

Significance
Because the cause of NIDDM is unknown in the majority
of cases, the search for defects leading to this condition
is of extreme importance for developing preventive and
therapeutic strategies.

Identification in the last few
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years of proteins involved in insulin signaling has provided
a starting point for the search for defects in insulin
signaling leading to insulin resistance.

Once the likely

defects are identified, it is possible that the development
of new antidiabetic compounds could be aimed at these points
of signal breakdown.

This study has included the

antidiabetic agent pioglitazone, a member of a novel class
of insulin-sensitizing compounds. This class of compounds is
known to lower blood glucose levels of diabetic mice by an
unknown mechanism that operates post insulin-receptor
binding.

CHAPTER III
MATERIALS AND METHODS

Materials

General Chemicals and Supplies

Chemicals
Guanidinium thiocyanate and f ormamide were purchased
from International Biotechnologies, Inc.

(New Haven, CT).

Acrylamide/Bis (40%), ammonium persulfate, and TEMED were
obtained from Bio-Rad (Richmond, VA).

Protein A-Sepharose

was purchased from Pharmacia (Milwaukee, WI). Nytran nylon
membranes (Schleicher and Schuell, Keene, NH) and Immobilon
PVDF membranes (Millipore, Bedford, MA) were used for
northern and western blotting, respectively.

Tris and

glycine were purchased from Fisher Scientific (Pittsburgh,
PA).

The Riboprobe kit, including all nucleotides,

polymerases, and transcription buffers were obtained from
Promega Corp.

(Madison, WI).

32 P-CTP,

14 C-Deoxyglucose,

and

the Enhanced ChemiLuminescence reagents were purchased from
Amersham (Arlington Heights, IL).

Luria-Bertani broth

(dehydrated) was obtained from Difeo (Detroit, MI).
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All
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other chemicals were purchased from Sigma Chemical Co.

(St.

Louis, MO).

Culture Reagents
Dulbecco's Modified Essential Medium (DMEM) with high
glucose (25 mM) or low glucose (5 mM) were obtained from
BioWhittaker (Walkersville, MD).

Fetal Calf Serum and Calf

Serum (heat inactivated), glutamine, trypsin-EDTA,
dexamethasone, IBMX (3-isobutyl-1-methylxanthine),
endotoxin-free water, Antibiotic/Antimycotic solution
(lOOX), and no-glucose DMEM (for glucose transport assays)
were all obtained from Sigma Chemical Corp.

(St. Louis, MO).

Porcine insulin obtained from Eli Lilly (Indianapolis, IN)
was used for the acute stimulation studies, and bovine
insulin (Sigma Chemical Corp.

(St. Louis, MO) was used

during differentiation of 3T3-Ll adipocytes.

cDNA Constructs

The Insulin Receptor
Mouse insulin receptor cDNA was obtained from Dr.
Graeme Bell (University of Chicago, Chicago, IL) in pUC, and
a 775 bp insert was subcloned into the EcoRI site of pGEM3Z
(2743 bp) giving a total construct size of 3518 bp.

For

Riboprobe preparation, the plasmid was linearized with
HindIII and T7 polymerase was used to make antisense mRNA.
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This probe hybridizes to two transcripts of 9.5 and 7.5 kb,
which differ by alternate poly-A site selection (59).

The Insulin Receptor Substrate-1
A rat cDNA insert of 5.5 kb in pBluescript was obtained
from Dr. Morris White (Joslin Diabetes Center, Boston, MA)
(85). For Riboprobe preparation, the construct was
linearized with BamHI and T7 polymerase was used to make
antisense mRNA.

The size of the transcript that hybridizes

with this Riboprobe is 9.5 kb.

Phosphatidylinositol 3'-kinase p85a
A rat cDNA insert of 1550 bp in pBluescript SK+/- was
obtained from Dr. Lewis Cantley {Harvard Medical School,
Boston, MA).

Digestion of this construct for Riboprobe

preparation with PvuII generates 3 fragments: a -2900 bp
vector fragment, a -700 bp fragment, and a -900 bp fragment.
The antisense mRNA probe created with T7 polymerase is
approximately 760 bp, transcribed from the -700 bp fragment.
The main transcript recognized by northern blotting in most
tissues is 7.5 kb.
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Antibodies

Anti-Insulin Receptor 8-subunit
A polyclonal antibody directed against the c-terminus
of the insulin receptor

~

subunit was obtained from Dr.

Morris White (Joslin Diabetes Center, Boston, MA).

Anti-Insulin Receptor Substrate-1

Immunoprecipitations.

A polyclonal antibody directed

against a c-terminal 14 amino acid peptide from rat liver
IRS-1 was purchased from Upstate Biotechnologies, Inc.

(Lake

Placid, NY) and used for immunoprecipitation of IRS-1 from
mouse primary adipocytes.

For immunoprecipitation of IRS-1

from mouse tissue, a polyclonal antibody directed against a
baculovirus-overexpressed IRS-1 was obtained from Morris
White (Joslin Diabetes Center, Boston, MA).

Western blotting. For primary adipocyte experiments,
rat experiments, and 3T3-Ll experiments, the anti-c-terminus
antibody described above was used for western blotting.

For

western blotting of mouse tissue immunoprecipitates, a
monclonal antibody directed against IRS-1 was obtained from
Morris White (Joslin Diabetes Center, Boston, MA).
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Anti-Phosphotyrosine
Tyrosine phosphorylation of the insulin receptor and
IRS-1 was detected using a monoclonal anti-phosphotyrosine
antibody, which was purchased from Upstate Biotechnologies,
Inc.

(Lake Placid, NY).

This antibody, named 4GlO, was

generated using phosphotyramine, and recognizes tyrosinephosphorylated proteins.

Anti-Phosphatidylinositol 3'-kinase p85a
For detection of PI3K p85a in all experiments except
for the primary adipocytes, a monoclonal antibody directed
against the N-terminal SH2 domain was obtained from Upstate
Biotechnologies, Inc.

(Lake Placid, NY).

In the primary

adipocyte experiments, a monoclonal antibody specific for
the SH3 domain of PI3K p85a, also purchased from Upstate
Biotechnologies, Inc., was used to measure PI3K p85a in
anti-IRS-1 immunoprecipitates.

Anti-Growth Factor Receptor Bound Protein-2
Anti-GRB2 monoclonal antibody was obtained from
Transduction Laboratories (Lexington, KY).

This antibody

was generated using the entire rat brain GRB2 protein as an
immunogen.
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Anti-Nck
Anti-Nck monoclonal antibody was obtained from
Transduction Laboratories (Lexington, KY).

It was generated

using an 11.5 kDa fragment corresponding to amino acid
positions 279-377 of the human Nck protein.

This antibody

cross-reacts with Nck in mouse and rat lysates.

Anti-Syp
For detection of Syp in all experiments, an anti-Syp
monoclonal antibody was obtained from Transduction
Laboratories (Lexington, KY).

The anti-Syp antibody was

produced using a polypeptide consisting of the N-terminal
177 amino acids of the human Syp protein.

Anti-Mouse
Anti-mouse Ig antibody (from sheep) was purchased from
Amersham (Arlington Heights, IL).

This antibody was

conjugated to horseradish peroxidase (HRP) for use as a
secondary antibody in enhanced chemiluminescence detection
(ECL) of proteins which are recognized by monoclonal (mouse)
primary antibodies.

Anti-Rabbit
Anti-rabbit Ig antibody (from donkey) was purchased
from Amersham (Arlington Heights, IL).

This antibody was

conjugated to horseradish peroxidase for use as a secondary

43

antibody in ECL detection of proteins which are recognized
by a polyclonal (rabbit) primary antibody.

Positive Controls

Insulin Receptor Substrate-1
Chinese hamster ovary cells overexpressing IRS-1 were
obtained from Morris White (Joslin Diabetes Center, Boston,
MA).

An aliquot of total cell lysate from these cells was

used as a positive control for all experiments involving the
detection of IRS-1.

Phosphatidylinositol 3'-kinase
Baculovirus-overexpressed PI3K p85a was obtained from
Dr. Lewis Cantley (Harvard Medical School, Boston, MA), and
an aliquot of this protein extract was used as a positive
control for all experiments involving detection of PI3K
p85a.

This protein migrated on SOS-PAGE as 85 kDa and was

recognized by the anti-PI3K p85a antibodies with high
affinity.
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Experimental Models and Design

Insulin Resistant Model (NIDDM)
All animal work up until the point of protein or RNA
extraction was performed at The Upjohn Company, including
blood glucose and serum insulin determinations.

C57 Control Mice
Male C57Bl-J6 mice 10-12 weeks of age were obtained
from Charles Rivers (Portage, MI) as control animals with
normal blood glucose (170±6 mg/dl or 9.4±0.3 mM) and normal
serum insulin levels ( 2 6±3 µU /ml or 1. 9x10-10 M) .

KKAY Diabetic Mice
Obese male KKAY mice 10-12 weeks of age were obtained
from the Upjohn Company (Kalamazoo, MI) for use as an animal
model of insulin-resistant diabetes (NIDDM) .

KKAY mice

result from a cross between glucose-intolerant black KK
female mice and yellow obese male AY mice.

The yellow

offspring KKAY mice are obese and insulin resistant, and
display marked hyperinsulinemia and hyperglycemia (19,36).
Due to the diabetic characteristics of the parental
strains, no genetically matched control exists for this
model for this model.

Therefore, C57Bl/6J mice were used as

controls because of the relatively normal glucose regulation
in the C57 strain.
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Feeding and Pioglitazone Treatment
All animals were housed individually and fed ad libitum
for four days prior to the experiment with or without
pioglitazone delivered as a food admixture at about 20
mg/kg/day.

It was previously determined that this dose and

delivery method produced maximal changes in blood glucose
and insulin sensitivity in mice within four days {Jerry
Colca, The Upjohn Company, Kalamazoo, MI, unpublished
observations).

Tissue Extraction and Animal Processing
On the fifth day from the start of drug treatment, the
mice were bled from the orbital sinus for measurement of
blood glucose concentrations and serum insulin levels,
decapitated, and liver and epididymal fat pads were excised.
The tissues were rapidly frozen in liquid nitrogen, shipped
to us on dry ice, and stored at -70° C until they were
processed by the RNA preparation or protein preparation
protocols.

Blood glucose levels were determined with an

Alpkem Glucose AuotoAnalyzer {Alpkem, Clackamas, OR), and
serum insulin levels were determined by radioimmunoassay as
previously described {162).
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Primary Adipocytes

Isolated/Primary Adipocyte Preparation
Animals used for the isolated adipocyte studies were
treated exactly as the above animals regarding feeding,
pioglitazone treatment, and animal sacrifice until the point
of tissue excision.

Epididymal fat pads from C57 and KKAY

mice treated with or without pioglitazone were placed into
KRB buffer (Krebs-Ringer-Bicarbonate-BSA

=

128 mM NaCl, 5 mM

KCl, 1.4 mM CaC1 2 , 1.3 mM MgS04 •7H20, 5 mM NaHC03 , 1.1 mM
glucose, and 2% BSA), quickly minced, and incubated in KRB
with 200 units/ml collagenase for 20 minutes.

Epididymal

fat pads from six animals from each group were combined to
generate a pool of adipocytes which were later split into
five samples to be individually stimulated with insulin.
The entire experiment was performed twice.

The collagenase-

digested fat pads were then passed through a cell strainer
which allowed digested cells and buffer to flow through.
The cells were washed twice in KRB buffer, then aliquots
were delivered into 0.4 ml microfuge tubes containing 0.1 ml
dinonylpthalate oil and centrifuged briefly at 3000 x g to
separate the buoyant fat cells from the non-adipose cells.
Adipocytes were then pooled again, pre-incubated in KRB for
five minutes, and cells were distributed in equal volume
aliquots (0.25 ml) for insulin stimulation.
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Insulin Stimulation
Equal volume aliquots of adipocytes (5 samples per
group) were incubated with 1x10-7 M insulin for two minutes
at 37° C with gentle shaking.

The samples were then quickly

frozen in a dry ice-acetone bath and stored at -70° C until
the time of the protein extraction.

Insulin Deficient Model (IDDM)
As with the insulin-resistant model, all animal work up
until the point of protein or RNA preparation was performed
at The Upjohn Company.

control Rats
Male Sprague-Dawley rats (160-180g) (Charles Rivers,
Portage, MI) were used as control animals for the
experiments dealing with insulin-deficient diabetes.

Insulin-Deficient Rats
Male Sprague-Dawley rats (160-180g) were made insulin
deficient by tail-vein injection of streptozotocin (65
mg/kg) and allowed to recover for 7 days prior to tissue
extraction for protein or RNA preparation.

These animals

displayed serum insulin levels of 4.2±1.0 µU/ml (3.1x1011±0. 7x10-11 M) compared to 22.8±1.8 µU/ml (1.7x10- 10±0.1x10-10 M)
in the controls.

Streptozotocin-treated rats also posessed
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high blood glucose levels (459±10 mg/dl or 25.5±0.5 mM) as
compared to control rats (151±2 mg/dl or 8.4±0.l mM).

Tissue Extraction and Animal Processing
On the day of the experiment, the rats were bled from
the orbital sinus for measurement of blood glucose
concentrations and blood insulin levels, decapitated, and
liver and epididymal fat pads were excised.

The tissues

were rapidly frozen in liquid nitrogen, shipped to us on dry
ice, and stored at -70°

c

until they were processed by the

RNA preparation or protein preparation protocols.

Blood

glucose levels were determined with an Alpkem Glucose
AuotoAnalyzer (Alpkem, Clackamas, OR), and serum insulin
levels were determined by radioimmunoassay as previously
described (162).

3T3-Ll Cells

Culture Conditions
3T3-Ll cells were obtained from the laboratory of Dr.
Howard Green (Harvard Medical School, Boston, MA).

3T3-Ll

cells were cultured on 100 mm plates (Corning, Oneonta, NY)
in a Napco Model 6200 incubator (Napco Scientific Co.,
Tualatin, OR) at 37°

c

and 10% C02 , and fed with the

appropriate medium every 2-3 days.

In the culturing of 3T3-

Ll adipocytes, "high glucose" medium refers to Dulbecco's
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Modified Eagle's Medium (DMEM) containing 4.5 g/L glucose
(450 mg/dl or 25 mM), and "low glucose" medium refers to
DMEM containing 1.0 g/L glucose (100 mg/dl or 5.5 mM).

Differentiation
Undifferentiated preadipocytes were grown to confluence
in high glucose DMEM + 10% calf serum.

Two days post-

conf luence, the cells were cultured in differentiation
medium (high glucose + 10% fetal calf serum, 1. 6x10-1 M
insulin, 0.25 µM dexamethasone, and 0.5 mM IBMX).

After two

days in differentiation medium, the cells were fed with high
glucose DMEM + 10% fetal calf serum and 1. 6x10-1 M insulin
for an additional two days.

The cells were then cultured in

high glucose DMEM + 10% fetal calf serum for 6 days, at
w~ich

time they were determined to be at least 90% confluent

by visual assessment.

Pre-feeding Conditions

Control Cells - Low Glucose, No Insulin.
Differentiated control cells were cultured in low glucose
DMEM + 0.5% serum substitute for 20-24 hours prior to the
experiment.

Insulin Resistant Cells - High Glucose, High Insulin.
Differentiated cells to be used as a model of the insulin
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resistant condition were cultured in high glucose DMEM +
0.5% serum substitute and 2x10~ M insulin for 20-24 hours
prior to the experiment.

Insulin debinding procedure.

This procedure was used

to release any bound insulin from the overnight high insulin
incubation, and was related to our laboratory through
personal communication (Jonathan Whittaker, SUNY Health
Science Center, Stonybrook, NY, phone conversation in April,
1992). It is a variation on a method which was previously
published (163). Immediately prior to glucose transport
assays or acute insulin stimulation of cells for protein
preparations, all cell groups were rinsed twice in PBS (pH
6.8), incubated in PBS (pH 6.8) + 1% BSA for 45 minutes, and
then

rins~d

again in PBS (pH 6.8).

Glucose Transport Assay
3T3-Ll cells were grown in Costar 6-well plates
(Cambridge, MA), differentiated, pre-fed, and incubated with
insulin debinding buffer prior to glucose transport assays.
The cells were then washed once with PBS (pH 7.4), followed
by a 15-minute incubation in a 22°

c

environmental shaker in

1 ml assay media (1 packet of Sigma DMEM base, 10 ml lOOmM
sodium pyruvate, 3.1 ml 0.5% phenol red, 5.96 g HEPES, 0.42
g sodium bicarbonate, 10 ml 200mM glutamine, 1 L pyrogenfree water, 0.1% BSA, pH 7.4) per well containing increasing
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amounts of insulin ( o, 1x10-10 M, 1x10-9 M, 1x10-s M, 1x10-7 M,
lxl0-6 M; or

o, 1x10-11 M lxl0-10 M, 1x10-9 M, lxl0-8 M, 1x10-7 M)

for each group of three wells.

100 µl

14

C-deoxyglucose was

then added for a final concentration of 0.5 µCi/ml, and the
cells were incubated for an additional 15 minutes.

The

cells were then washed three times in ice-cold PBS (pH 7.4)
containing 10 mM glucose, 0.9 ml 0.5 N NaOH was added to
each well, and the plates were incubated at 37° for 30
minutes.

These cell lysates were then removed to 18 ml

liquid scintillation vials, and 105 µl of glacial acetic
acid plus 10 ml of Beckman Ready Value Scintillation Fluid
(Beckman, Inc. Fullerton, CA) was added prior to reading the
amount of

14

C-deoxyglucose uptake on a Beckman LS5801 liquid

scintillation counter.

This insulin dose response curve was

performed with each 3T3-Ll experiment to be certain that the
high insulin/high glucose pre-incubation made the cells
insulin resistant, and also to ensure that the control cells
were indeed responsive to insulin.

RNA Preparation

Extraction Methodology

RNAse Inactivation of Supplies
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Glassware.

All Corex tubes (Dupont, Wilminton, DE) and

glassware were baked at 225° C overnight to inactivate
RNAses.

Plasticware and water.

To inactivate RNases, all pipet

tips and aqueous solutions were treated with diethyl
pyrocarbonate (DEPC) and autoclaved prior to use.

Isolation of RNA from Animal Tissue
Isolation of total RNA was performed essentially by the
method of Chomczynski and Sacchi (120,164).

Frozen tissue

pieces of 0.1-0.4 g (liver) or 0.2-1.1 g (epididymal fat)
were homogenized for 10 seconds with a Tekmar Tissuemizer
(Cincinnati, OH) in 5 ml of ice-cold RNA homogenization
buffer (4 M guanidinium thiocyanate, 22 mM sodium citrate,
0.5% Sarkosyl, and 0.1 M 2-mercaptoethanol) in a 15 ml
polystyrene Falcon tube (Becton Dickinson Labware, Franklin
Lakes, NJ).

Following homogenization, samples were

centrifuged at 8000 x g at 4° C for 15 minutes in a Sorvall
RC2B high speed centrifuge (Dupont, Wilmington, DE).

The

infranatants from this spin, between the cell debris and the
uppermost lipid layer, were then transferred to a Corex tube
and mixed vigorously with 0.5 ml 2 M NaOAc (pH 4.0), 5 ml
phenol, and 1 ml chloroform:isoamyl alcohol (49:1), followed
by an incubation on ice for 15 minutes.

Samples were then

centrifuged at 8000 x g at 4° C for 30 minutes, the top
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aqueous fraction was transferred to another Corex tube, and
an equal volume (4 ml) of isopropanol was added.

Samples

were mixed thoroughly, then incubated for 2 hr at -70°

c.

Following this precipitation, the samples were spun at 8000
x g at 4°

c

for 45 minutes.

The supernatant was poured off,

the pellet was resuspended in 1 ml of RNA homogenization
buffer, and 100 µl of 3 M NaOAc (one tenth volume) plus 1 ml
isopropanol (equal volume) were added to the samples.
Following another 2 hr incubation at -70°

c, the samples

were spun for 45 minutes at 8000 x g and 4° C to precipitate
the RNA.

The supernatant was then poured off and the pellet

was washed with 1 ml of 70% ethanol followed by a 3 minute
spin at 8000 x g at 4°

c.

The ethanol supernatants were

poured off, the pellets were allowed to dry, and then the
RNA samples were resuspended in 0.2-1 ml DEPC-treated water.
Samples were stored at -70°

c.

Isolation of RNA from 3T3-Ll Cells
Two lOOmm plates of differentiated, pretreated 3T3-Ll
cells were combined for each data point. The prefeed media
was aspirated, the cells were washed once with PBS, and then
5 ml of RNA homogenization buffer was split between the two
plates.

Cells were scraped from the two plates with a

sterile rubber policeman and combined into a Corex tube.

To

ensure that the cells were lysed, the samples were pipetted
up and down in a 10 ml pipette 5 times. From this point on,
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the samples were treated exactly as the infranatants from
the first spin in the animal tissue extractions as described
above.

Concentration Determination
The UV absorbance of the RNA sample was read at 260A on
a Beckman DU-64 Spectrophotometer (Beckman Instruments,
Inc., Arlington Heights, IL) using the Nucleic Acid Soft-Pac
Module software(Beckman Instruments, Inc.).

The conversion

factor used to determine the concentration of the RNA
samples was 1 Optical Density unit = 40 µg/ml.

Northern Blot Analysis

Electrophoresis
Electrophoresis was performed essentially by the method
of Fourney, et al.

(165).

10 µg of total RNA at a

concentration of 1 µg/µl in RNA loading buffer (0.04 mg/ml
ethidium bromide, 53% formamide, 17% formaldehyde, 7%
glycerol, and 5.6% saturated bromophenol blue in lx 3-[Nmorpholino]propanesulfonic acid (MOPS)) was loaded per lane
on 1.1% agarose gels.

An RNA ladder was run on each gel to

ensure that the band resulting from hybridization was the
correct transcript size, and also to maintain the correct
orientation of the samples.

The gels were electrophoresed

at 90V for 4 hours in lX MOPS (0.02 M MOPS, 5 mM NaOAc, 1 mM
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EDTA, pH 7.0), after which the gels were washed twice in lOX
SSC (1.5 M NaCl, 0.15 M citrate, pH 7.0) at room temperature
for 20 minutes.

Transfer of RNA to a Membrane by Northern Blotting
Following the two lOX SSC washes described above, the
RNA was transferred overnight by capillary action to a
Nytran nylon membrane (Schleicher and Schuell, Keene, NJ) by
the method of Fourney and coworkers (165).

The RNA was then

UV crosslinked to the membrane using a Stratagene UV
Stratalinker™ 1800 (Stratagene, La Jolla, CA).

The nylon

membranes were then placed on a UV transilluminator and
photographed with a Polaroid MP-3 Land Camera, with an
orange filter and Polaroid Type55 positive/negative black
and white film.

Exposure was for 25 seconds, with an

aperture seting of f/8, followed by a 20 second development.

Loading Correction
Loading correction for RNA blots was based on the
amount of 28S ribosomal RNA per lane, as measured by 2dimensional densitometric analysis of the negative from the
photograph of the northern blot.

The 28S signal on the

negative from the amount of RNA loaded per lane (10 µg) was
determined to be in the linear range of the film under our
photographic conditions, as determined by Bonini and Hofmann
( 166) .
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Riboprobe Preparation and Hybridization

DNA Template Preparation
ONA templates for Riboprobe preparation were isolated
from bacterial slushes containing the appropriate plasmid
using the QIAGEN kit {Chatsworth, CA).

Ten µl of the

appropriate bacterial slush stock (which has an OD of 1.0
when read at 600A with a spectrophotometer) was used to
inoculate 200 ml of Luria-Bertani broth with 150 µg/ml
ampicillin.

The culture was grown overnight to a

concentration of cells which had an optical density of 1.0
when read at 600A.

The 200 ml culture was then split into

four 50 ml conical centrifuge tubes in equal aliquots and
centrifuged at 1000 rpm at 4°C in a table-top Sorvall
RT6000B.

The supernatant was discarded, and each pellet was

resuspended in 10 ml Pl buffer {100 µg/ml RNAse A, 50 mM
Tris/HCl, and 10 mM EDTA pH 8.0).

Ten ml of P2 buffer {200

mM NaOH, 1% SOS) was added to the samples, and after a
gentle shaking, the samples were incubated for 5 minutes at
room temperature.

Ten ml of P3 was added, the samples were

gently mixed, incubated on ice for 20 minutes, and then spun
at 10,000 x g for 30 min.

The supernatant was then passed

through a cell strainer (Beckton Dickinson Labware, Franklin
Lakes, NJ) into the Qiagen Q500 column, which was preequilibrated with 10 ml of QBT buffer (750 mM NaCl, 50 mM
MOPS, 15% ethanol, pH 7.0, and 0.15% Triton X-100). ·The
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column was then washed with 30 ml of buffer QC (1.0 M NaCl,
50 mM MOPS, 15% ethanol, pH 7.0), followed by elution with
15 ml buffer QF (1.25 M NaCl, 50 mM MOPS, 15% ethanol, pH
8.2).

The DNA samples were then precipitated with 0.7

volume of isopropanol, spun at 16,000 x g for 30 minutes at
room temperature, washed with 70% ethanol, and resuspended
in 50 µl TE (10 mM Tris-Cl, pH 7.4, 1 mM EDTA, pH 8.0).

The

concentration of the purified plasmid was determined by
reading the absorbance of the sample at 260A.

The

conversion factor used to determine the concentration of the
DNA was 1 OD unit equals a concentration of 50 µg/ml.

DNA

templates were then linearized using 0.5 µg/µl DNA, 20 units
restriction enzyme, 4 µl lOX REACT Buffer, and 12 µl DEPCH20).

Probe Preparation
32

P- labeled Riboprobes were prepared according to the

recomendations of the supplier (Promega, Madison, WI).
Linearized DNA was incubated with the transcription reagents
(1.2 mM ATP, 1.2 mM GTP, 1.2 mM UTP, 10 mM OTT, 25 units/µl
RNAsin, lX transcription buffer, 5 µM CTP, 5-10 units T7 RNA
polymerase, and 50 µCi of a- 32P-CTP) for 1 hour at 37°

c,

after which RNAse-free DNAse (lU/µl) was added, and the
probes were incubated for an additional 15 minutes to remove
any remaining template.

Riboprobes were then subjected to a

phenol-chloroform extraction and precipitated with 1/10
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volume NaOAc and 2.5 volumes of 100% ethanol by incubation
for 1-2 hours -70°

c.

The supernatant was poured off, the

pellet was resuspended in 50 µl TE, and then the probe was
passed over a 5 Prime-3 Prime column (Westchester, PA).

The

effluent from a 4 minute spin at 1670 x g through this
column was used as the purified

32

P-labeled Riboprobe for

hybridization.

Hybridization
Hybridization of Riboprobes to the Nytran-bound RNA was
performed as previously described (18).

Nytran membranes

were pre-wet in 2X SSC prior to prehybridization for 2 hours
at 65°

c

with 10 ml hybridization buffer (4X SSPE, 50%

formamide, 10% dextran sulfate, 5X Denhart's solution, 0.1%
SDS, and 0.1 mg/ml soncated denatured salmon sperm DNA) in a
Hybaid Mini Hybridization oven (Hybaid, Middlesex, UK).
lOOX Denhart's (2% polyvinylpyrrolidone, 2% BSA, 2% Ficoll)

and 2 OX SSPE ( 3 M NaCl, 0. 1 7 M NaH2P04 • H20, 0. 02 M EDTA) were
used as stock solutions to make the hybridization buffer.
Following prehybridization,

32

P-labeled Riboprobes were

denatured by boiling for 5 minutes with an additional 1 mg
of denatured sonicated salmon sperm DNA, and added to the
hybridization buffer for an overnight hybridization (16-18
hours) in the Hybaid oven.

After the hybridization,

northern blots were washed twice at room temperature for 5
minutes (2X SSC, 0.1% SDS), twice at 70° C (2X SSC, 0.1%
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SOS) for 30 minutes, and twice at 70° C in O.lX SSC, 0.1%
sos for 30 minutes.

Blots were then either filmed with

Amersham Hyperfilm MP (Arlington Heights, IL) at -70°

c with

an intensifying screen for 16-72 hours, or washed further
with 100 ml of 2X SSC containing 3 µg/ml RNAse A and 0.005
units RNAse Tl/ml to remove nonspecific binding.

Protein Preparation

Extraction Methodology

Animal Tissue
Total protein was prepared from animal tissue by an
adaptation of the method previously described by Rice, et

al. (84).

Liver and epididymal fat tissue pieces of 0.1-1.2

g were homogenized with a Tekmar Tissuemizer (Cincinnati,
OH) in 3 ml of ice cold homogenization buffer (0.02 M Tris
base, 0.15 M NaCl, 1% Triton X-100, 0.03 M Na 4P 20 7 •10 H20, 1
mM Na 3V04 ,

10 µM E-64, 1 mM PMSF, 3 mM EOTA, 50 µM leupeptin,

and 10 µg/ml aprotinin).

Cell lysates were then centrifuged

at 30,000 x g for 30 minutes at 4° C, and the infranatant
was passed through a Millex AP20 syringe filter (Millipore
Corp., Bedford, MA) to remove any remaining lipids.
Concentration determinations were made, sample aliquots were
taken for immunoprecipitation or dilution in Laemmli buffer,
and the samples were stored at -70°

c.
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3T3-Ll Cells
Four lOOmm plates of confluent, differentiated, prefed
3T3-Ll adipocytes were used per data point.

One ml of ice-

cold homogenization buffer was added to each plate, the
cells were scraped with a rubber policeman, and pipetted up
and down repeatedly to ensure cell lysis.

The lysates from

the four plates were then combined into one tube,
centrifuged at 30,000 x g for 30 minutes at 4°
through a Millex AP20 syringe filter.
at -70°

c,

and passed

Samples were stored

c.

Isolated Mouse Adipocytes
Equal amounts of isolated mouse adipocytes were
homogenized in 500 µl of ice-cold homogenization buff er
using a tef lon Dounce homogenizer connected to a Glas-Col
variable speed laboratory motor (Terre-Haute, IN) at speed 2
for 10 seconds, followed by centrifugation at 16,000 x g for
30 minutes.

The infranatant was passed through a Millex AP4

syringe filter, and the samples were then stored at -70°

c.

Concentration Determination
The concentration of each protein sample was determined
the day of the experiment, and sample aliquots were taken
for immunoprecipitation and SDS-polyacrylamide gel
electrophoresis.

Concentrations were determined by the

Lowry method (167) using the BioRad De Assay (Bio-Rad,
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Hercules, CA).

The absorbance of the samples at 750A was

compared against a standard curve of varying concentrations
of BSA in homogenization buffer.

Immunoprecipitation

Sample and Antibody Concentrations
For immunoprecipitation of IRS-1 from isolated primary
adipocytes, 1 mg total protein in 500 µl was incubated with
8 µg anti-IRS-1 antibody (Upstate Biotechnologies, Inc.).
For immunoprecipitation of IRS-1 from animal tissue, 10 µl
of the anti-baculovirus IRS-1 antibody was added to 1 mg
total protein in 400 µl, as recommended by the supplier
(Morris White, Boston, MA).

Methodology
Cell lysates were incubated with anti-IRS-1 antibodies
overnight (16-18 hours) at 4°

c

with gentle rocking.

Following the overnight incubation, 100 µl of protein ASepharose (Pharmacia, Milwaukee, WI) was added and the
samples were rocked for an additional 2 hours at 4°

c.

The

samples were then centrifuged at 16,000 x g for 2 minutes,
and the pellets were washed twice with 1 ml wash buffer (140
mM

NaCl, 2.7

mM

KCl, 10

mM

Na 2HP04 1.8

mM

KH2P04 , 100 µM

Na3V04 , and 1% NP40), with a 2 minute centrifugation at
16,000 x g between washes.

After the second wash, the
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pellet was resuspended in 100 µl of 2X Laemmli Sample
Buffer(lX

=

62.5 mM Tris, 10% glycerol, 2%

sos,

10% 2-

mercaptoethanol, and .001% bromophenol blue) and boiled for
6 minutes prior to electrophoresis.

Western Blot Analysis

SOS-PAGE
Total cell lysates in lX Laemmli sample buffer or
immunoprecipitates were electrophoresed on 7.5% or 12%
polyacrylamide gels essentially according to the method of
Laemmli (168).

Equal amounts of protein (between 10 and 30

µg for total lysates) or equal volumes of immunoprecipitate
were electrophoresed on duplicate gels at 150 V for 1.5
hours using the Bio-Rad Mini-Protean II Dual Slab Cell (BioRad, Richmond, CA).

On each gel a molecular weight marker

(Bio-Rad, Richmond, CA) was included for orientation and
size determination purposes.

Where appropriate, a positive

control for IRS-1 or PI3K p85a was used to confirm that the
correct protein was visualized during immunostaining.
Proteins were then electrophoretically transferred to
Immobilon P membranes (Millipore Corp., Bedford, MA) using
the Bio-Rad Mini-Transblot electrophoretic transfer cell
(Bio-Rad, Richmond, CA) for 3-4 hours at 100

v.

One set of

the duplicate blots was used for Coomassie staining,
followed by total protein quantitation of the stained blot.
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This quantitation was used for normalizing for differences
in loading between lanes.

The other set of blots was

immunostained as described below with the appropriate
antibodies.

Immunostaining
Western blots were blocked 2 hours or overnight in
Tris-Buffered Saline (TBS = 0.9% NaCl, 20 mM Tris, pH 7.4)
with 5% BSA, then washed four times for 10 minutes with TBStween (TBST) wash buffer (TBS, 0.05% Tween-20, 0.1% BSA) and
incubated with primary antibody for 2 hours in antibody
dilution buffer (TBS, 0.05% Tween-20, 1% BSA).

Blots with

mouse tissue anti-IRS-1 immunoprecipitates were probed with
the monoclonal anti-IRS-1 antibody and required an overnight
incubation with the primary antibody.

Following the primary

antibody incubation, the blots were washed four times for 10
minutes in TBST, then incubated for 30 minutes in antibody
dilution buffer with the appropriate secondary antibody.
After the incubation with the secondary antibody, the blots
were washed four times for 15 minutes in TBST before
exposure to the ECL reagents for 1 minute.

The excess ECL

liquid was allowed to drain off, and the blots were placed
between two sheets of acetate and exposed to Hyperf ilm MP or
Hyperfilm ECL for a period of 10 seconds to 45 minutes.
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Primary antibody dilutions.

The anti-IR

antibody was used at a 1:2000 dilution.

~-subunit

The anti-IRS-1

monoclonal antibody and anti-phosphotyrosine antibody were
used at a 1:1000 dilution, and the anti-IRS-1 c-terminal
polyclonal antibody was used at a 1:1500 dilution.

Both

anti-PI3K p85a antibodies were used at a dilution of 1:8000.
Anti-GRB2, anti-Nck, and anti-Syp antibodies were used at a
1:4000 dilution.

Secondary antibody dilutions.

The anti-mouse HRP-

linked secondary antibody was used at a dilution of 1:7500.
The anti-rabbit HRP-linked secondary antibody was used at a
1:6000 dilution.

Image Analysis

All autoradiographs from northern blots and ECL western
blots were quantitated by video densitometry using the Ambis
Image Acquisition Analysis system (San Diego, CA).

This

system was also used for determination of molecular weights
of proteins and sizing of mRNA transcripts by comparison of
sample lanes with molecular weight lanes or RNA ladder
lanes.
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Statistics

All data were analyzed for statistical significance
using the Graphpad Instat software (Graphpad Software, San
Diego, CA).

Two-Group Experiments

Parametric Test
For most experiments with two groups, such as the rat
experiments (control vs. streptozotocin-treated) or the 3T3Ll cell culture experiments (low glucose/no insulin vs. high
glucose/high insulin), the data was analyzed with an
unpaired Student's T-Test using a two-sided p-value.

A p-

value less than 0.05 was considered significant.

Nonparametric Test
For two-group experiments in which the standard
deviations were significantly different between groups and
were also not normalized by log, square-root, or reciprocal
transformation of the data, the Mann-Whitney nonparametric
test with a two-sided p-value was used to analyze the data.
A p-value less than 0.05 was considered significant.
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Experiments with More Than Two Groups

Ordinary ANOVA
In most experiments with more than two groups, such as
the mouse, primary adipocyte, or 3T3-Ll acute insulin
studies, the data was analyzed using ANOVA with the Tukey
multiple comparisons post-test.

A p-value of less than 0.05

was considered significant.

Kruskal-Wallace Nonparametric Test
For experiments with more than two groups in which the
standard deviations were significantly different between
g~oups

and were also not normalized by log, square-root, or

reciprocal transformation of the data, the Kruskal-Wallace
nonparametric test with the Dunn's multiple comparisons test
was used to analyze the data.
considered significant.

A p-value less than 0.05 was

CHAPTER IV
RESULTS

Glycemic State and Insulin Levels of KKAY Mice
The blood glucose and serum insulin levels were
determined from blood samples taken from the animals at the
time of tissue extraction at The Upjohn Company.

The blood

glucose level for the control C57 mice was 170±6 mg/dl or
9.4±0.3 mM (±SEM), while the average blood glucose level in
KKAY mice was 494±25 mg/dl or 27.4±1.3 mM.

Pioglitazone

treatment of KKAY mice lowered the blood glucose level to
257.4±18.3 mg/dl (14.3±1.0 mM).
Serum insulin levels were similarly elevated in the
KKAY mice as compared to control C57 mice, and these levels
were also partially corrected by pioglitazone treatment.
C57 mice had an average serum insulin concentration of
25. 8±2. 7 µU/ml or 1. 9x10- 10±0. 2x10- 10 M (±SEM), while the
average serum insulin level of KKAY mice was 476.9±54.4
µU/ml or 3. 5x10-9 ±o. 4x10-9 M.

Pioglitazone treatment of KKAY

mice corrected the average serum insulin levels to
299.5±33.2 µU/ml (2.2X10~±0.2x10~ M).
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Expression of Insulin Signaling Components in Animal NIDDM
The expression of the insulin receptor (IR), IRS-1,
PI3K p85a, GRB2, Nck, and Syp was analyzed in three animal
groups: C57 control mice (C), KKAY diabetic mice (D), and
KKAY mice treated with pioglitazone (D+P) •

The observed

protein and transcript sizes are shown in table 1.

All data

in figs. 2 and 3 are expressed as percent of control C57
expression for each group, ± standard error of the mean
(SEM).

Protein Levels of Insulin Signal Components
In order to determine if the protein levels of IR, IRS1, p85a, GRB2, Nck and Syp were altered in insulin resistant
animals as compared to control nondiabetic animals, and to
determine if pioglitazone treatment corrected these
alterations, protein extracts of epididymal fat and liver
tissue from nondiabetic C57 mice, obese KKAY insulinresistant mice, and KKAY mice treated with pioglitazone were
analyzed by western blotting.

The abundance of the proteins

studied was determined to be roughly the same between liver
and adipose in the control animals.
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Table 1.-- Observed Protein and mRNA Transcript Sizes of
Signaling Components
Protein size

mRNA size

Gene

(kDa)

(kb)

IR

96.5

9.5, 7.5

IRS-1

162.9

9.5

P85a

84.9

7.5

GRB2

25.7

Nck

44.2

Syp

69.6

The Insulin Receptor
In both epididymal fat and liver, the IR levels in KKAY
mice were reduced to 17±3% and 33±4% of C57 control levels,
respectively, and these were increased significantly with
pioglitazone treatment to 32±3% and 57±5% of control levels
(fig. 2, upper panels).

IRS-1
IRS-1 protein levels were not significantly different
between C57 and KKAY mice, and pioglitazone treatment did
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not significantly alter IRS-1 protein abundance in either
tissue (fig. 2, middle panels).

PI3K p85a
The expression of PI3K p85a was measured using a
monoclonal antibody directed against the SH2 domains of
p85a.

As seen in fig. 2, two major bands of approximately

the same size are recognized by this antibody in fat tissue.
This may be due to cross-reactivity with another protein,
p87~,

which has high homology to p85a (128).

While both

proteins may associate with the pllO subunit (128), we found
that only the lower band (p85a) associated with IRS-1 on
insulin stimulation of isolated adipocytes (fig. 11).

In

addition, the lower band lined up with the baculovirusexpressed p85a positive control, while the upper band did
not.

Also, the recent availability of an antibody specific

for the SH3 domains of only p85a detected only the lower of
the two bands in fat tissue (data not shown).

For these

reasons, the lower band observed in fat tissue was
quantitated as p85a.
PI3K p85a protein levels were significantly lower in
KKAY fat (47±3 % of control) and fully corrected by
pioglitazone administration to 103±15% of control levels
(fig 2, panel E).

However, p85a levels in liver were not

significantly different between C57 and KKAY mice, and were
not altered by pioglitazone treatment (fig. 2, panel F).

71
Liver

Epididymal Fat

IR

75

so
25

D

T
IRS-1

0
11s~E~~~~~~~~.-F~~~~~~~--,

150

-=--:;,;;;==···
p85o:

c

D

D+P

c

D

D+P

Fig. 2. The protein levels of the insulin receptor (IR),
IRS-1, and PI3K p85a are depicted in C57 (C), KKAY (D), and
KKAY + pioglitazone (D+P) as% Control C57, with fat data on
the left and liver data on the right.
Inside each graph is
a representative western blot for the respective protein,
shown with an n=3 for c, D, and D+P. The upper panels
represent protein levels of IR, the center panels represent
the protein levels of IRS-1, and the lower panels show the
protein levels for PI3K p85a. For all experiments, n=12 and
all values represent the mean ± SEM (* indicates p<0.-05, **
indicates p<0.01, and*** indicates p<.001).
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Pioglitazone treatment did not significantly alter the
expression of the insulin receptor, IRS-1, or p85a proteins
in the control animals (data not shown).

GRB2, Nck, and Syp
GRB2, Nck, and Syp levels were regulated in an opposite
manner from IR, IRS-1, and p85a levels.

GRB2.

GRB2 protein abundance was significantly

elevated in KKAY epididymal fat (321±25% control - fig. 3,
panel A).

In liver tissue this elevation was not as great

(118±6% control), although it was significant (fig 3, panel
B).

Pioglitazone administration did not alter GRB2 levels

to a large extent, but it did lower the slightly elevated
KKAY liver GRB2 levels to control levels.

Nck.

Like GRB2, Nck levels were much higher in KKAY

fat as compared to C57 (186±12% control), and there was a
smaller but significant elevation of Nck in KKAY liver
compared to C57 (124±7% control - fig. 3, middle panels).
Again, there was little effect of pioglitazone treatment on
Nck protein levels in the treated KKAYtissues.

~

Syp protein levels were 43±11% higher in KKAY fat

than in C57, and 25±4% higher in KKAY liver compared to C57.
Both of these increases were statistically significant
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Fig. 3. The protein levels of the GRB2, Nck, and Syp are
depicted in C57 (C), KKAY (D), and KKAY + pioglitazone (D+P)
as% Control C57, with fat data on the left and liver data
on the right. Inside each graph is a representative western
blot for the respective protein, shown with an n=3 for c, D,
and D+P. The upper panels represent the protein levels of
GRB2, the center panels represent the protein levels of Nck,
and the lower panels show the protein levels for Syp. For
all experiments, n=12 and all values represent the mean ±
SEM (* indicates p<0.05, ** indicates p<0.01, and ***
indicates p<.001).
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(p<0.05).

Pioglitazone treatment did not significantly

change Syp levels in fat, but it did lower liver syp levels
in liver tissue toward control levels (fig. 3, lower
panels).

Pioglitazone treatment did not significantly alter

the expression of GRB2, Nck, or Syp in control animals (data
not shown).

mRNA Levels of Insulin Signaling Components
PI3K has been implicated in insulin stimulated glucose
transport (99,102), and KKAY mice display a defect in
insulin's ability to promote glucose uptake in fat and
muscle (18).

Therefore, potential mechanisms for lowered

levels of IR and p85a proteins were determined by analyzing
the mRNA abundance of these transcripts in tissues of
nondiabetic C57 mice, obese KKAY insulin-resistant mice, and
KKAY mice treated with pioglitazone.

IRS-1 mRNA abundance

was also determined in the same groups.

A northern blot for

the insulin receptor showed transcripts of two lengths:
kb and 7.5 kb.

9.5

The difference in size between these two

transcripts results from differential poly-A site selection
and there is no known functional difference between the 9.5
and 7.5 kb transcripts (59).

The IRS-1 mRNA transcript is

9.5 kb long, and the primary p85a mRNA size is 7.5 kb.

The

abundance of these transcripts was determined as described
in Materials and Methods above.
figures 4, 5, and 6.

Data are summarized in
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Insulin Receptor
In epididymal fat and liver, receptor mRNA levels were
slightly less in the KKAY mice as compared to C57, although
the only significant difference was in the liver with the
7.5 kb transcript (figure 4).

Pioglitazone administration

did not have a significant effect on receptor mRNA levels.
There was no detectible difference in the 9.5/7.5 kb ratio
between any of the groups.

IRS-1
IRS-1 mRNA levels were significantly lower in KKAYfat
and liver (53.3±4.3 and 50.7±6.2% control, respectively)
than in the C57 controls, with no correction by pioglitazone
treatment (figure 5).

However, this difference in IRS-1

mRNA abundance was not associated with a significant change
in the IRS-1 protein levels (fig. 2, middle panels).

PI3K p85a
In epididymal fat, p85a mRNA abundance was not
significantly different between the C57 and KKAY mice,
although the mean p85a mRNA level was 75% of control.
Pioglitazone treatment did not significantly alter the p85a
mRNA levels in the treated KKAY group as compared to the
untreated KKAY group (fig. 6).

The mRNA levels of p85a were

not determined in liver because there was no difference in
the level of p85a protein in this tissue.
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Fig. 4. The mRNA levels for the insulin receptor in C57
(C), KKAY (D), and KKAY + pioglitazone (D+P) are depicted as
mean% control C57, ± SEM. Left, IR RNA abundance in fat;
right, IR RNA in liver. Solid bars represent the abundance
of the 9.5 kb receptor transcripts and hatched bars
represent the 7.5 kb transcript abundance. n=12 for both
fat and liver data.
* represents a statistical difference
with a p value less than 0.05.
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Fig. 5. The mRNA levels for IRS-1 in C57 {C), KKAY (D), and
KKAY + pioglitazone (D+P) are depicted as mean % control
C57, ± SEM. Left, IRS-1 RNA abundance in fat; right, IRS-1
RNA in liver. n=12 for both tissues, and * represents a
statistical difference with a p value less than 0.05
relative to control.
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Fig. 6. The levels of mRNA transcripts PI3K p85a in
epididymal fat from C57 (C), KKAY (D), and KKAY +
pioglitazone (D+P) are depicted as mean% control C57, ±
SEM. n=12 for both tissues, and * represents a statistical
difference with a p value less than 0.05 relative to
control.
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GRB2. Nck, and Syp
The cDNA for GRB2, Nck, and Syp were not available at
the time of the study; thus, the RNA levels for these
components in this model are unknown.

Since the differences

in GRB2 and Nck protein levels between C57 and KKAY mice
were very large, in the future it would be interesting to
determine if such differences also exist at the RNA level.

Function of the Insulin Receptor and IRS-1 in Animal NIDDM

Insulin-Stimulated Tyrosine Phosphorylation
of the Insulin Receptor And IRS-1
In order to study the role of insulin receptor function
in insulin resistance, primary adipocytes were isolated from
epididymal fat of C57 mice, KKAY mice, and KKAY mice
pretreated with pioglitazone.

These adipocytes were then

stimulated acutely with insulin, and the tyrosine
phosphorylation of the insulin receptor

~

subunit and IRS-1

was assayed by western blotting with an anti-phosphotyrosine
antibody.

A representative blot is shown in fig. 7, and the

graphed results of the cumulative data are illustrated
in figures 8, 9, and 10.

Although the representative blot

shows an n of 2, The n for these experiments was 10 cell
aliquots per group.

The data are represented as the percent

phosphorylation of the unstimulated C57 control group, ±
SEM.
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Insulin Receptor Phosphorylation
In control C57 mice, acute insulin stimulation resulted
in an 11.4-fold increase in insulin receptor
tyrosine autophosphorylation (fig. 8).

~

subunit

In adipocytes from

KKAY mice, insulin stimulation failed to increase the
tyrosine phosphorylation of the insulin receptor relative to
the KKAY basal tyrosine phosphorylation, and the receptor
was not made any more sensitive to insulin in stimulating
tyrosine phosphorylation of its

~

subunit by prior

pioglitazone treatment of the mice (fig. 8).

Also, basal

phosphorylation of the receptor in KKAY mouse adipocytes was
significantly higher (about 6-fold) than basal tyrosine
phosphorylation of the receptor in C57 mice.

This is likely

due to the higher level of circulating insulin in the KKAY
mice relative to the control mice.

Pioglitazone treatment

did not significantly lower the basal phosphorylation of

KKAY insulin receptors.

Therefore, there appears to be both

a decreased number of receptors (fig. 2) and a decrease in
the responsiveness of the receptors to insulin in KKAY mice.
Because pioglitazone treatment partially corrects
receptor number back toward control levels, the mean
phosphorylation per unit receptor appears to be lowered to
approximately a third of the phosphorylation per receptor in
untreated KKAY mice (fig.9), although this change was not
quite significant (p=0.0594).

However, the analysis of the

data as phosphorylation per receptor did emphasize the
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Fig. 7. Phosphotyrosine content of the insulin receptor
(IR) and IRS-1 was detected by western blotting with antiphosphotyros ine antibodies of lysates from isolated
adipocytes unstimulated or stimulated acutely with 100 nM
insulin for 2 minutes. This representative blot shows an
n=2 for each group: D=KKN (unstimulated), D/I=KKAY
(stimulated) , D/P=KKAY pretreated with pioglitazone
(unstimulated), D/P/I=KKAY pretreated with pioglitazone
(stimulated), C=C57 (unstimulated), C/I=C57 (stimulated).
IR and IRS-1 bands are indicated by arrows to the right of
the blot.
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Fig. 8. cumulative graphed results of acute insulinstimulated phosphorylation of the insulin receptor ~ subunit
in isolated adipocytes are depicted as mean % unstimulated
control (C57) ± SEM, n=lO. Data were accumulated from antiphosphotyrosine western blots such as is shown in fig. 7.
*** represents a statistical difference (p<0.001) between
the bracketed groups. ns=not significant (p>0.05)
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Fig. 9. Cumulative graphed results of receptor tyrosine
phosphorylation per unit receptor in isolated adipocytes are
depicted as mean % unstimulated control (C57) ± SEM, n=lO.
Data were accumulated from anti-phosphotyrosine western
blots such as is shown in fig. 7 and anti-IR~ western blots
of the same samples.
*** represents a statistical
difference (p<0.001) between the bracketed groups. ns=not
significant (p>0.05).
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Fig. 10. cumulative graphed results of acute insulinstimulated phosphorylation of IRS-1 in isolated adipocytes
are depicted as mean % unstimulated control (C57) ± SEM,
n=lO. Data were accumulated from anti-phosphotyrosine
western blots such as is shown in fig. 7.
* represents a
statistical difference (p<0.05) as compared to the
unstimulated control group.
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increased basal phosphorylation of the receptor in the KKAY
mice as compared to control.

IRS-1 Phosphorylation
The insulin-stimulated tyrosine phosphorylation of IRS1 in control mice was not as pronounced as that of the
insulin receptor (fig. 7 and fig. 10).

Insulin stimulation

of the control isolated adipocytes caused an increase in
tyrosine phosphorylation of IRS-1 by 72.4±21.1% over
nonstimulated cells (fig. 10), while in KKAY adipocytes
insulin failed to stimulate tyrosine phosphorylation over
the nonstimulated KKAY adipocytes.

As with the insulin

receptor phosphorylation, pioglitazone treatment did not
make the KKAY cells any more sensitive to insulin in
phosphorylating IRS-1.

In contrast to receptor

phosphorylation, the basal tyrosine phosphorylation of IRS-1
in KKAY adipocytes or pioglitazone-treated KKAY adipocytes
was not elevated relative to the IRS-1 tyrosine
phosphorylation in unstimulated C57 adipocytes (fig. 10).
The IRS-1 phosphorylation per unit IRS-1 was not determined
since there was not a significant difference in IRS-1
protein levels between the three groups.
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Insulin-Stimulated Association of IRS-1
with PI3K p85a
Following insulin stimulation of the receptor tyrosine
kinase and tyrosine phosphorylation of IRS-1, IRS-1 is known
to associate with PI3K p85a via the phosphorylated YMXM
motifs on IRS-1 and the SH2 domains of p85a.

Therefore, the

association of IRS-1 with p85a on insulin stimulation was
compared between C57 and KKAY mice.

Since pioglitazone

partially corrects blood glucose levels, and PI3K has been
linked to glucose transport, the KKAY mice treated with
pioglitazone were included in this comparison.

In addition,

as is shown in figure 2, pioglitazone corrected PI3K p85a
protein levels in epididymal fat to C57 levels and thus may
result in increasing the association of PI3K p85a with IRS1.

However, given the above results from figures 7 and 10,
one would expect that in the absence of insulin-stimulated
IRS-1 phosphorylation in KKAY mice or pioglitazone-treated
KKAY mice, there would be no insulin stimulation of p85a
associated with IRS-1 in either group.

To determine if the

pioglitazone correction of PI3K p85a levels resulted in a
correction of insulin signaling at this level, lysates from
the isolated adipocytes from C57, KKAY, and pioglitazonetreated KKAY mice with or without acute insulin stimulation
were subjected to an immunoprecipitation with a polyclonal
anti-IRS-1 antibody.

These immunoprecipitates were then
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size-fractionated on SOS-PAGE and immunoblotted for PI3K
p85a to observe the amount of p85a which associates with
IRS-1 on insulin stimulation in each group.

A

representative blot is shown in fig. 11, and the cumulative
data from an n of 10 are summarized in fig. 12.

As is

shown in fig. 12, acute insulin stimulation of C57
adipocytes caused p85a to associate with IRS-1 to a level of
217.2±25.8% of the amount of p85a associated with IRS-1 in
unstimulated control cells.

Like the tyrosine

phosphorylation of IRS-1, the basal association of p85a with
IRS-1 in KKAY and pioglitazone-treated KKAY groups was about
the same as the basal level in unstimulated C57 adipocytes,
and this association was not elevated by insulin
stimulation.

The Effects of Insulin and Glucose on Signal Transduction
Components

Expression of Insulin Signaling Components in the Presence
of High Glucose or High Glucose plus High Insulin
To determine if the alterations in expression and
function of insulin signaling components observed above in
the KKAY mice was due to the presence of the high glucose
and high insulin levels in these animals, two other models
were used.

First, differentiated 3T3-Ll adipocytes
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pretreated with high glucose (25mM or 450mg/dl) plus high
insulin (2 µM) medium overnight were used in an attempt to
mimic the hyperglycemia and hyperinsulinemia of KKAY mice.
This caused the cells to be resistant to insulin stimulation
of glucose uptake (fig. 13).

3T3-Ll cells pretreated

overnight in low glucose (5.5 mM or 100 mg/dl) and very low
insulin medium were used as control cells to represent the
normoglycemic state.
In addition, a rat model of IDDM displaying high
glucose (459±10 mg/dl) relative to control rats (151±2
mg/dl) was used to determine whether the presence of high
circulating levels of glucose in the absence of high insulin
levels could affect the expression of these proteins.
Streptozotocin treatment of rats induces IDDM by causing
destruction of the pancreatic

~

cells, and in this model

lowered blood insulin levels to roughly 20% of the insulin
levels in the control rats (data not shown).

3T3-Ll Cells
In the 3T3-Ll model, the expression of all six of the
signaling components and insulin-stimulated phosphorylation
of the insulin receptor and IRS-1 were studied.

Fig. 13

shows the degree of insulin resistance caused by high
insulin and glucose incubation as assayed by

14

C-deoxyglucose

uptake upon acute insulin stimulation with increasing
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Fig. 11. The amount of PI3K p85a associating with IRS-1 was
detected by western blotting of anti-IRS-1
immunoprecipitates from isolated adipocytes unstimulated or
stimulated acutely with 100 nM insulin for 2 minutes. This
representative blot shows an n=2 for each group: D=KKAY
(unstimulated), D/I=KKAY (stimulated), D/P=KKAY pretreated
with pioglitazone (unstimulated), D/P/I=KKAY pretreated with
pioglitazone (stimulated), C=C57 (unstimulated), C/I=C57
(stimulated). MW=molecular weight markers. The two bands
in the MW lane are 106,000 (upper band) and 80,000 (lower
band). The lane labeled PI3K was loaded with PI3K p85a
positive control. The labels on the right of the figure
indicate the positions of PI3K p85a migration and the IgG
heavy chain of the precipitating antibody.
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Fig. 12. cumulative graphed results of acute insulinstimulated association of PI3K p85a with IRS-1 in isolated
adipocytes are depicted as mean % unstimulated control (C57)
± SEM, n=lO. Data were accumulated from anti-p85a western
blots of IRS-1 immunoprecipitates such as is shown in fig.
11. ** represents a statistical difference (p<0.01) between
the bracketed groups. ns=not significant (p>0.05).
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Fig 13. Representative insulin dose-response curves are
shown for insulin-stimulated 14C-deoxyglucose uptake in 3T3Ll adipocytes pre-fed overnight with DMEM containing 5.5mM
glucose (LG,-I, thick solid line,+), 5.5mM glucose+
2x10~ insulin (LG,+I, thick dashed line, O), 24.4 mM
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represents the average amount of 14C-deoxyglucose uptake
(n=6) at the given insulin concentration, and the lines
represent a sigmoidal regression of each data set.
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amounts of insulin.

High glucose in the absence of high

insulin caused a decrease in the maximal insulin
stimulation of glucose transport, while high insulin with or
without high glucose fully attenuated the ability of the
cells to take up glucose on insulin stimulation.

Insulin receptor.

The expression and phosphorylation

of the insulin receptor in insulin-resistant 3T3-Ll
adipocytes were altered in a manner similar to theexpression
and phosphorylation of the receptor observed in KKAY mice.
The receptor protein levels in the insulin-resistant cells
was lowered to 33.6±3.3% of control cell receptor expression
(fig. 14, left panel), much like the lower expression seen
in KKAY mice as compared to C57.

The levels of 9.5 and 7.5

kb mRNA transcripts were significantly lowered to 58.75±3.2
and 75.3±3.6% of control cells (fig. 14, middle), a larger
difference than was seen in the receptor RNA levels between
the KKAY and control mice.

Another interesting observation

was that the high glucose and high insulin incubation caused
a shift in the ratio of the 9.5 to 7.5 kb transcripts.

In

control cells, there was an 11% difference between the
percent 9.5 kb transcript in the total receptor RNA and the
7.5 kb transcript in the total.

In the cells treated with

high insulin and high glucose, this difference disappeared
(fig. 14, right).
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Fig. 14. Graphed results of the protein and RNA levels of
the insulin receptor in 3T3-Ll cells. LG-I=3T3-Ll cells
pre-fed overnight in low glucose (4.4 mM) DMEM; HG+I=3T3-Ll
cells pre-fed overnight in high glucose (24.4 mM) DMEM with
2x10·6 M insulin. Left, protein levels are represented as %
control (LG-I) ± SEM, n=22. Center, the RNA levels are
graphed as %control (LG-I) ± SEM for both the 9.5 and 7.5 kb
species, n=16. The solid bar represents the amount of 9.5
kb transcript, while the hatched bar represents the amount
of 7.5 kb transcript. Right, the relative ratios of the 9.5
and 7.5 kb transcripts are shown as % of the total insulin
receptor transcripts (9.5+7.5 kb) for both treatment groups.
* indicates a significant difference (p<0.05) as compared to
control or between the bracketed groups.
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The acute insulin stimulation of control 3T3-Ll cells
resulted in a 25-fold increase in the tyrosinephosphorylation of the insulin receptor

~

subunit, as

detected by western blotting with anti-phosphotyrosine
antibodies (fig. 15).

A one-minute insulin stimulation was

used in these experiments, since the receptor and IRS-1
tyrosine phosphorylation was maximal in control cells at one
minute (fig. 16, lanes 4 and 5).

Like the KKAY isolated

adipocytes, the insulin-resistant cells had a much higher
level of basal tyrosine phosphorylation than the control
cells, and were unable to respond to insulin by further
phosphorylation of the receptors (fig. 15, left).

Likewise,

expression of data as phosphorylation per receptor
exaggerated the basal phosphorylation of the receptor in the
insulin resistant cells as compared to control (fig. 15,
right), owing to decreased receptor numbers in insulintreated cells.

Such observations were consistent with those

seen in adipocytes isolated from insulin-resistant KKAY mice
(fig. 9) •

IRS-1.

The expression of IRS-1 in the insulin-

resistant 3T3-Ll cells was also regulated in much the same
way as IRS-1 expression in KKAY mice.

The protein levels of

IRS-1 were not significantly different between control and
insulin-resistant cells, as shown in fig. 17 (left panel).
In addition, like in the animal model of insulin resistance,
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Fig. 16. The time course for insulin-stimulated tyrosine
phosphorylation of IRS-1 and the insulin receptor in control
3T3-Ll cells, as observed with western blotting with antiphosphotyrosine antibodies. Phosphorylated IRS-1 and IR
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the mRNA abundance for IRS-1 in the insulin-resistant 3T3-Ll
cells was significantly lower than in the control cells
(fig. 17, right).
The insulin stimulated tyrosine phosphorylation of IRS1 was attenuated by high insulin and high glucose incubation
of 3T3-Ll cells, as shown in fig. 18.

Although this was

also seen in the KKAY adipocytes, there was a difference
between these two models in that the basal phosphorylation
of IRS-1 was elevated in the in vitro model of insulin
resistance relative to control cells (fig. 18). In the
animals, there was not a difference in the basal tyrosine
phosphorylation of IRS-1 between KKAY and C57 mice.

Because

there was not a large difference in the protein levels of
IRS-1 between control 3T3-Ll cells and the insulin-resistant
3T3-Ll cells, the results for phosphorylation per IRS-1
(fig. 18, right) did not differ greatly from the total
phosphorylation data (fig. 18, left).

PI3K p85a.

As in the animal epididymal fat tissue, the

PI3K monoclonal (anti-SH2) antibody recognized two bands.
The lower of these two bands comigrated with the
baculovirus-produced p85a positive control on SOS-PAGE
western blots.

The expression of PI3K p85a was not altered

by incubation of 3T3-Ll cells with high glucose and high
insulin (fig. 19, left), although this treatment caused an
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Fig. 17. Graphed results of the protein and RNA levels of
IRS-1 in 3T3-Ll cells. LG-I=3T3-Ll cells pre-fed overnight
in low glucose (4.4 mM) DMEM; HG+I=3T3-Ll cells pre-fed
overnight in high glucose (24.4 mM) DMEM with 2x10·6 M
insulin. Left, protein levels are represented as % control
(LG-I) ± SEM, n=22. Right, the RNA levels are graphed as
%control (LG-I) ± SEM, n=16.
* indicates a significant
difference (p<0.05) as compared to control.
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Fig. 19. Graphed results of the protein and RNA levels of
PI3K p85a in 3T3-Ll adipocytes. LG-I=3T3-Ll cells pre-fed
overnight in low glucose (4.4 mM) DMEM; HG+I=3T3-Ll cells
pre-fed overnight in high glucose (24. 4 mM) DMEM with 2x10·6
M insulin. Left, protein levels are represented as % control
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* indicates a significant
difference (p<0.05) as compared to control.
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increase in the variance of these cells which may have
obscured a slight increase.

This differs from the mouse

experiment, where the expression of p85a protein in KKAY
mice was 53% lower than the expression in C57 control mice.
Also dissimilar from the mouse experiment was that the RNA
levels of PI3K p85a were lowered by 31±3.4% by high glucose
and high insulin incubation of 3T3-Ll cells (fig. 19,
right), whereas the RNA levels in KKAY fat did not differ
significantly from the RNA levels in the control mice (fig.
6, left), even though KKAY mice are also hyperglycemic and
hyperinsulinemic.

GRB2, Nck, and Syp.

Incubation of 3T3-Ll cells in high

insulin and high glucose resulted in a significant elevation
of GRB2 and Nck protein levels, but did not change the
expression of Syp protein (fig. 20).

The elevation of these

proteins in this model of insulin resistance is consistent
with the higher expression of these proteins in KKAY mice as
compared to C57 mice (fig. 3); however, the magnitude of
these increases were much smaller in this in vitro model
than in the in vivo model.

GRB2 and Nck levels in these

insulin-resistant 3T3-Ll cells were 135.7±8.1% and 117±3.1%
of control, respectively, while the levels of these proteins
in KKAY mice were 321±25.4% and 185.6±12.2% of the
respective levels of GRB2 and Nck in control mice.
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Fig. 20. The expression of GRB2, Nck, and Syp protein in
3T3-Ll adipocytes. LG-I=3T3-Ll cells pre-fed overnight in
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Rat Streptozotocin-Induced IDDM
The expression of all six signaling components was
studied in this in vivo model of IDDM to determine if high
glucose levels in the absence of high insulin are associated
with any alterations in the levels of these proteins.

Insulin receptor.

The protein levels of the insulin

receptor were altered somewhat differently in fat and liver
of streptozotocin-treated rats as compared to control rats.
In liver, the expression of the insulin receptor was
significantly elevated to 183±25% of control (fig. 21,
left).

In epididymal fat, the average receptor protein

level was 130.6±11.4% of control, although this difference
was not significant (fig. 22, left).

In both tissues, the

mRNA levels were significantly elevated in the
streptozotocin-treated rats compared to the control rats.
The elevation in liver tissue was associated with an
increase in the 9.5 kb transcript (fig. 21, center).

The

higher mRNA levels in epididymal fat were mainly associated
with an increase in 7.5 kb transcripts, although the 9.5 kb
receptor mRNA was also significantly higher than in the
control animals (figure 22, center).
In addition to the differences in receptor protein
expression between the two groups in both tissues, the ratio
of the 9.5 to 7.5 kb transcripts was tissue-specific as
well.

In liver tissue, control rats had a significantly
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Fig. 21. Graphed results of the protein and RNA levels of
the insulin receptor in rat liver. C=control rats; STZ=rats
made insulin-deficient by streptozotocin treatment. Left,
protein levels are represented as % control ± SEM, n=9.
Center, the RNA levels are graphed as %control ± SEM for
both the 9.5 and 7.5 kb species, n=7 control and 9 STZ. The
solid bar represents the amount of 9.5 kb transcript, while
the hatched bar represents the amount of 7.5 kb trnscript.
Right, the relative ratios of the 9.5 and 7.5 kb transcripts
are shown as % of the total insulin receptor transcripts
(9.5+7.5 kb) for both treatment groups. * indicates a
significant difference {p<0.05) as compared to control or
between the bracketed groups.
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higher ratio of 7.5 kb transcripts, and streptozotocin
treatment reversed this ratio {fig. 21, right).

In

epididymal fat, the control animals had a significantly
higher ratio of 9.5 kb transcripts, while the
streptozotocin-treated animals had roughly an equal amount
of each transcript {fig. 22, right).

IRS-1.

The mRNA levels for IRS-1 were also increased

in both fat {fig. 23, right) and liver tissue {fig. 24) of
streptozotocin-diabetic rats as compared to control rats.
This increase was to 198.6±28.5% control and 217±18.4%
control in fat and liver, respectively.

Unlike the

expression of the insulin receptor, the elevated IRS-1 mRNA
levels were not associated with a concomitant increase in
the IRS-1 protein in fat tissue.

In fact, IRS-1 protein

levels in epididymal fat of streptozotocin-treated rats was
significantly lowered to 62.2±4.7% of control {fig. 23,
left).

The protein levels for IRS-1 in rat liver were not

measurable on western blots due to a nonspecific band which
was recognized by several anti-IRS-1 antibodies.

This

protein was very highly expressed in comparison to IRS-1,
and the proximity of this protein to IRS-1 on SOS-PAGE gels
was so close that its signal overshadowed IRS-1 expression.
Substantial evidence suggests that this band represents a
nonspecific protein interaction.

First, the band migrated
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Fig. 22. Graphed results of the protein and RNA levels of
the insulin receptor in rat epididymal fat.
C=control rats;
STZ=rats made insulin-deficient by streptozotocin treatment.
Left, protein levels are represented as % control ± SEM,
n=9. Center, the RNA levels are graphed as %control ± SEM
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The solid bar represents the amount of 9.5 kb transcript,
while the hatched bar represents the amount of 7.5 kb
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transcripts (9.5+7.5 kb) for both treatment groups. ** and
*** indicate a significant difference (p<0.01 and p<0.001,
respectively) as compared to control or between the
bracketed groups.
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C=control rats;
STZ=streptozotocin-treated rats. Left, protein levels are
represented as % control ± SEM, n=9. Right, the RNA levels
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Fig. 24. Graphed results of the RNA levels of IRS-1 in rat
liver. C=control rats; STZ=streptozotocin-treated rats.
The RNA levels are graphed as %control ± SEM, n=18 control
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*** indicates a significant difference
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slightly ahead of the positive control, which normally lined
up with IRS-1.

Secondly, IRS-1 is expressed at very low

levels in all tissues studied, and the expression of this
band was much too high to have been IRS-1.

Third, there was

a faint band that lined up with the positive control which
was not quantitatable due to the high expression of the
nonspecific band (data not shown).

PI3K p85a.

In epididymal fat, streptozotocin treatment

had no effect on the expression of p85a at the protein or
mRNA levels (fig. 25).

In contrast, liver tissue of

streptozotocin-treated rats showed a 68.9±12.7% increase in
the expression of p85a protein over the expression in liver
tissue from control rats (fig. 26, left).

This increase in

p85a protein was not clearly reflected at the RNA level, as
there was only a slight nonsignif icant increase in p85a mRNA
between control and streptozotocin-treated animals in liver
tissue (fig. 26, right).

GRB2. Nck, and Syp.

Like the receptor, IRS-1, and

p85a, the expression of GRB2, Nck, and Syp tended to be
regulated in the opposite manner in this model of IDDM
(streptozotocin-treated rats) from the NIDDM model (KKAY
mice), as shown in figs. 27 and 28.

In epididymal fat and

liver tissue, there was no difference in the expression of
GRB2 between control and streptozotocin-treated rats (figs.
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Fig. 25. Graphed results of the protein and RNA levels of
PI3K p85a in rat epididymal fat. C=control rats;
STZ=streptozotocin-treated rats. Left, protein levels are
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Right, the RNA levels are graphed as %control± SEM,-n=6.
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Fig. 27. The expression of GRB2, Nck, and Syp protein in
rat epididymal fat.
C=control rats; STZ=streptozotocintreated rats. Left, protein levels of GRB2; center, protein
levels of Nck; and right, protein levels of Syp are graphed
as % control ± SEM, n=9 control and 8 STZ.
* indicates a
significant difference (p<0.05) as compared to control.
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Fig. 28. The expression of GRB2, Nck, and Syp protein in
rat liver. C=control rats; STZ=streptozotocin-treated rats.
Left, protein levels of GRB2; center, protein levels of Nck;
and right, protein levels of Syp are graphed as % control ±
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* and *** indicate a significant difference of
p<0.05 or p<0.001 as compared to control, respectively.
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27 and 28, left).

Nck protein levels were significantly

reduced to 70.87±6.5% of control in liver tissue of
streptozotocin-treated animals, while Nck expression was
unchanged in epididymal fat (figs. 27 and 28, center).

Syp

protein levels were significantly decreased to 71.8±9.3 and
61.2±4.4% of control in fat and liver tissues, respectively
(figs. 27 and 28, right).

CHAPTER V
DISCUSSION

Because NIDDM is associated with a variety of metabolic
derangements (2-5,120), and the cause of insulin resistance
probably lies in a post-receptor defect in most cases, this
project focused on studying early insulin signaling events
as possible sites of defects.

Earlier signal transduction

defects would likely lead to multiple downstream
derangements, particularly if alterations occurred before
insulin's signal branched to elicit its many different
cellular effects.
The current study indicates that there are multiple
alterations in the expression and function of components
involved in the first stages of insulin signal transduction
in diabetic KKAY mouse tissues as compared to control
nondiabetic animals.

The expression and function of the

insulin receptor, IRS-1, and PI3K p85a were found to be
defective to varying degrees in KKAY mice.

Conversely,

GRB2, Nck, and syp levels were elevated in KKAY mice as
compared to nondiabetic controls.
However, results from the in vitro model of insulin
resistance suggest that many of these alterations are likely
115
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a result of hyperinsulinemia and hyperglycemia associated
with the diabetic condition.

Also, hyperglycemia with

hypoinsulinemia tended to regulate the expression of these
signaling components in the opposite direction from
hyperglycemia with hyperinsulinemia relative to control
animals.

Therefore, the pathophysiology associated with the

insulin-resistant diabetic condition of KKAY mice,
particularly hyperinsulinemia, may be responsible for the
observed alterations.

PI3K p85a expression was the

exception, as it was decreased in adipose from KKAY mice
relative to control, but not significantly altered in 3T3-Ll
cells pre-fed with high levels of glucose and insulin.
Pioglitazone treatment of KKAY mice had little effect
on the expression or function of any of the proteins
studied.

While pioglitazone treatment increased PI3K p85a

levels in KKAY fat to control levels, this increase in
expression did not result in an increase in p85a associated
with IRS-1 on insulin stimulation of adipocytes from
pioglitazone-treated KKAY mice compared to untreated KKAY
mice.

Therefore, pioglitazone probably elicits its insulin-

sensitizing effect in this model of insulin-resistant
diabetes by a mechanism other than the alteration of the
expression or function of early signaling components.
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Proteins with Altered Expression or Function in KKAY Mice or
Streptozotocin-treated Rats

The Insulin Receptor

Expression
The protein levels of the insulin receptor in fat and
liver from insulin-resistant KKAY mice were lower than
receptor levels in either tissue from nondiabetic C57
controls (fig. 2).

However, high amounts of insulin have

been shown to cause internalization and degradation of the
insulin receptor (169,170), and the enzyme responsible for
at least part of the degradation of the insulin receptor is
a lysosomal thiol protease (170).

In the 3T3-Ll cells pre-

fed with high insulin and high glucose, a similar decrease
in the amount of insulin receptor protein was seen (fig.
14), suggesting that the lower levels of receptor protein in
the KKAY mice may be due to the high circulating insulin
levels in these animals.
Further evidence supporting this concept lies in the
regulation of the RNA levels for the insulin receptor.

In

KKAY mice, the RNA levels for the insulin receptor are not
significantly lower than in C57 mice with the exception of
the 7.5 kb transcript in liver (fig. 4).

A significant

difference in receptor RNA levels existed in the 3T3-Ll
cells pre-fed with high glucose and high insulin as compared
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to control cells, although this difference was only about
25% {fig. 14).

This is about the same magnitude as the

difference between the mean receptor RNA levels between KKAY
and C57 mice.

The fact that this difference is significant

in the cell culture experiment, but not the animal
experiment, may be a result of the smaller variation in cell
culture as opposed to animal studies.

The differences in

mRNA {about 25% control) are much smaller than the
differences in protein in either study, suggesting a
regulation of the receptor at the protein level, most likely
due to insulin receptor internalization and degradation.
Comparable results were found by Ludwig, et al. in livers of
genetically obese and hyperinsulinemic mice, where receptor
number was decreased even though mRNA levels were increased
compared to controls {171).
Interestingly, insulin receptor mRNA levels were
upregulated in fat and liver of the insulin-deficient
streptozotocin-diabetic rats compared to control tissues,
and liver tissue demonstrated a significant concordant rise
in receptor protein (fig. 21 and fig. 22).

Similar results

were found by Tozzo, et al., where both the 7.5 and 9.5 kb
transcripts were increased 10-fold in liver tissue of
streptozotocin-treated rats (172).

This increase was due to

an increase in transcription of the insulin receptor gene,
and also resulted in increased insulin binding to liver
plasma membranes by 40% (172).

In this case, the RNA and
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protein were upregulated in the absence of insulin.

Such

changes may represent cellular compensations to upregulate
receptors when there is insufficient insulin to elicit
normal effects.
If this were the case, there should have been a similar
rise in insulin receptor mRNA in the insulin-resistant 3T3Ll cells or tissues from KKAY mice, as opposed to the
observed decrease in both models (fig. 4 and fig. 14).
Therefore, high insulin levels probably lower insulin
receptor mRNA levels as well as receptor protein levels in

KKAY mice.

To support the data shown in figs. 2, 4, 14, 21,

and 22, the expression of the insulin receptor was regulated
in a manner similar to KKAY mice in liver and muscle of
insulin-resistant ob/ob mice (173), while receptor levels
were increased in tissues of streptozotocin-treated rats
( 173) .
The physiological significance of insulin receptor
regulation can be partially explained using the concept of
spare receptors.

Normal cells possess many more insulin

receptors than are necessary to produce maximal cellular
responses in the presence of physiological concentrations of
insulin (174).

Insulin-stimulated glucose oxidation is

maximal in isolated fat cells when only 8-10% of the
receptors are occupied {174).

There are two major

advantages to the presence of spare receptors in insulinsensi ti ve tissues.

First, spare receptors protect cells

120
from hypoglycemia following the surge of insulin in response
to a glucose challenge because the maximal effects are
attained at an insulin concentration well below the
concentration needed to bind all of the receptors.
Secondly, spare receptors help to prevent hyperglycemia when
there is a sudden loss of receptors (174).

However, spare

receptors are not actually "spare," since decreasing
receptor number causes a subsequent loss in sensitivity,
requiring more insulin to elicit the maximal cellular
effects (174).

Therefore, the lower amount of insulin

receptors in KKAY mice probably contributes to the diabetic
condition by making the cells less responsive to insulin,
even though the receptor number was above the 8-10% of
control involved in binding insulin in normal cells.
Pioglitazone treatment significantly increased receptor
protein levels toward control levels in KKAY epididymal fat
(p<0.05 between KKAY and KKAY + pioglitazone treatment),
although there was not a statistically significant effect of
pioglitazone on receptor levels in liver tissue (fig. 2).
There was also no significant effect of pioglitazone on
receptor mRNA levels.

This seems to indicate that the

effect of pioglitazone treatment on receptor expression, if
any, is secondary to some other effect of pioglitazone.

The

effect of pioglitazone treatment on receptor number in fat
is likely a result of the lowering of serum insulin levels
and a subsequent partial alleviation of the insulin
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dowhregulation of the receptor (20).

This effect does not

seem to change receptor binding, however, since pioglitazone
was not found to significantly alter insulin binding
(17,20,44).

Therefore, while increased receptor number

should increase insulin binding (174), the small increase in
receptor number resulting from pioglitazone treatment of

KKAY mice may not be large enough to create a significant or
detectable change in insulin binding.

Alternate Splicing of the Insulin Receptor
Although several transcript sizes of the insulin
receptor have been reported (59), there are four main
splicing products that result from alternate splicing of
exon 11 in the a subunit (57,58,75-81,175,176) and alternate
poly-A site selection (59).

Agarose gel electrophoresis of

total RNA can only distinguish between the 9.5 kb and 7.5 kb
species, which differ by alternate poly-A-site selection
(59).

The poly-A site selection occurs independently of the

splicing of exon 11, resulting in four possible products.
The ratio of 9.5 to 7.5 kb transcripts did not differ
between KKAY and control mice (data not shown), nor did the
ratio of exon 11+ to exon 11- between these groups (Susan
Sell, phone conversation, March 1994) in muscle, fat, or
liver tissue.

In the 3T3-Ll adipocytes pre-treated with

high glucose and high insulin, the ratio of 9.5 to 7.5 kb
transcripts changed from a significantly higher percent of
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9.5 than 7.5 kb transcripts in the control cells (55.66±1.3%
9.5 kb, 44.3±1.3% 7.5 kb; p<0.001, n=16) to an even ratio
(50.5±1.3% 9.5, 49.5±1.3% 7.5; p>0.05, n=16), as is shown in
fig. 14.

Therefore, insulin and glucose may regulate the

poly-A site selection of this transcript, though there is no
known functional difference between the 9.5 and 7.5 kb
transcripts (59).
In contrast to the insulin-resistant animals, the
streptozotocin-treated rats showed opposite trends for
insulin receptor transcript poly-A site selection compared
to transcripts from control animal tissues (fig. 21 and fig.
22).

There was also a tissue-specific difference in the

ratio of these transcripts, even in the control animals.
While control liver had a higher percentage of 7.5 kb
transcripts, fat tissue possessed a higher percentage of 9.5
kb transcripts.

Streptozotocin-treatment reversed this

ratio in liver (fig. 21) and equalized it in fat (fig. 22),
indicating that the streptozotocin-induced diabetic
condition may alter RNA processing.

It is interesting to

note that treatment of 3T3-Ll adipocytes with high glucose
and high insulin had the same effect on the ratio of these
transcripts as did streptozotocin-induced diabetes on such
transcripts in fat tissue.

Due to the similarity of the

tissue and cells (fat and adipocytes), it may be that poly-A
site selection is altered by the elevated glucose present in
both experimental models.

However, the same effect was not
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seen in hyperglycemic KKAY mice as compared with C57 mice
(data not shown), although there are many more factors
influencing the tissues in this polygenic model (36,37).

Kinase Activity
Insulin-stimulated adipocytes isolated from C57 animals
showed an 11-fold increase in the tyrosine-phosphorylation
of the insulin

receptor~

subunit (fig. 7 and fig. 8), while

control 3T3-Ll cells showed a 25-fold increase when acutely
stimulated with insulin.

This response was obliterated in

insulin-resistant, hyperglycemic KKAY mice as well as in
3T3-Ll cells pre-fed with high insulin and high glucose,
suggesting that the high insulin and high glucose levels may
contribute to the insulin resistance of these cells (fig. 7,
fig. 8, and fig. 15).

In both the animal and cell culture

models of insulin resistance, the basal tyrosine
phosphorylation of the receptor

~

subunit was increased well

above the basal tyrosine phosphorylation of the receptor in
control cells (fig. 8 and fig. 15), probably due to the high
levels of circulating insulin.

Another possibility is that

the high glucose concentrations in both models could be
inhibiting the insulin receptor kinase, since it has been
shown that incubation of rat-1 fibroblasts with high glucose
concentrations led to inhibition of the receptor kinase
(42,43).

The insulin dose-response curves in 3T3-Ll cells

reflected an inhibition of insulin-stimulated glucose uptake
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in the cells pre-fed with high glucose only (fig. 13), but
it was also evident that treatment with high levels of
insulin alone caused an even greater inhibition (fig. 13).
It is possible that hyperphosphorylation of the insulin
receptor could lead to inhibition of its kinase activity.
There is evidence that the c-terminal tyrosines 1316 and
1322 may play a role in negatively regulating the insulin
receptor kinase (63,64).

Mutation of these tyrosines to

phenylalanine caused an increase in the phosphorylation of
the receptor and IRS-1, along with an increase in p85
association with IRS-1, an increase in PI3K activity, and an
increase in MAP kinase activity (64).

Therefore, when these

residues are phosphorylated, they may play a role in turning
off receptor signaling in normal cells when the insulin
levels are high enough to elicit the desired effects, or
these residues could possibly inhibit the receptor in the
hyperinsulinemic condition.
However, because of the nature of the methodology used
to measure phosphotyrosine in this study, it is possible
that acutely-stimulated receptor phosphorylation could not
be measured due to the high amount of basal phosphorylation
of the

~

subunit in the insulin-resistant condition.

While

there are many potential tyrosine phosphorylation sites per
receptor, it is not known whether the binding of one or more
antibody molecules to phosphotyrosines on the receptor could
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block further antibody binding to additional phosphorylated
tyrosines after insulin stimulation.
Another factor to be considered is that although the
insulin resistant cells of both models have a higher degree
of basal receptor tyrosine phosphorylation, they also have
fewer receptors.

To aid in interpreting this data, the

phosphorylation per unit receptor was graphed in fig. 9 and
fig. 15.

Presentation of the data in this way accentuated

the increased basal phosphorylation of the

~

subunit in the

KKAY mice and 3T3-Ll cells treated with high glucose and
high insulin.
Similar results were found by Kanety, et al. in the
sand rat model of insulin-resistant diabetes (177).

In this

model, the animals were induced to a state of
hyperinsulinemia in the absence of hyperglycemia by altering
their diet.

This state of insulin resistance was associated

with a decrease in the number of insulin receptors and an
inhibition of the receptor kinase, while the basal receptor
phosphorylation was increased (177).

Upon restriction of

the diet, these receptor defects were brought back to
control levels.

Comparable results were also found in

adipocytes from NIDDM patients, where there was an observed
decrease in the insulin-stimulated tyrosine phosphorylation
of insulin receptors (53).

Such patients did not have a

decreased number of insulin receptors (53), presumably due
to the tighter metabolic control maintained in human-studies
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compared to the extreme hyperglycemia and hyperinsulinemia
in experimental KKAY mice.
In the present study, pioglitazone had no effect on the
insulin-stimulated insulin receptor kinase
autophosphorylation in KKAY mice (fig. 8 and fig. 9).

This

differs slightly from reports by Kellerer, et al. and
Maegawa, et al. in which troglitazone or pioglitazone
treatment reversed the inhibition of the insulin receptor
kinase in rat-1 fibroblasts pre-fed with high glucose
(42,43).

Pioglitazone was also shown to correct receptor

phosphorylation defects in Wistar fatty rats (16) and highfat-fed rats (44).

In another study, however, pioglitazone

increased insulin stimulation of PI3K activity without
increasing receptor phosphorylation in 3T3-Ll cells
overexpressing insulin receptors and in L6 myotubes (48).
The difference between these studies and ours could
represent a difference in the systems studied, or possibly a
difference in methodology.

In the present study, whole cell

lysates were examined, so that the receptor number and
phosphorylation is indicative of the total amount of
receptor

~

subunits.

The other studies purified the insulin

receptors using wheat germ agglutinin (WGA).
carbohydrate moieties present on both a and

WGA binds
~

subunits,

although the a subunits are glycosylated to a greater extent
than

the~

subunits (74).

Such methods would purify and

evaluate mostly whole receptors.

My study examined only the
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receptor

~

subunit population, which may include

phosphorylated

~

subunits separated from a subunits during

degradation of the receptor.

This possibility exists

because phosphotyrosines in the juxtamembrane domain
(67,169,178,179), kinase domain (169,178,180), and

c-

terminus (66,169) have all been shown to be involved in
receptor internalization.

Such measures may reflect

elevated baseline phosphorylation of the

~

subunit, thus

diminishing the observed proportion of insulin-stimulated
phosphorylation of the receptor.

IRS-1

Expression
The protein levels of IRS-1 were not significantly
different between control and KKAY mice in fat or liver
(fig. 2), even though the IRS-1 mRNA levels were
significantly lower in KKAY mice as compared to control in
both tissues (fig. 5).

These findings differ slightly from

previous findings by Saad, et al. in another animal model of
NIDDM, ob/ob mice.

The protein levels for IRS-1 in ob/ob

mice were found to be significantly lower in liver tissue as
compared to nondiabetic ob/+ controls, while IRS-1
expression was unaltered in muscle tissue (173).
Unfortunately, fat tissue was not a part of that study.
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Saad, et al. also investigated the expression of IRS-1
protein in the streptozotocin-treated rat model of IDDM.
IRS-1 protein expression was unaltered in either liver or
muscle tissue from streptozotocin-treated rats as compared
to control (173).

In our study, IRS-1 mRNA abundance was

increased in fat and liver tissues of streptozotocin-treated
diabetic animals as compared to nondiabetic controls (fig.
23 and fig. 24, respectively).

However, IRS-1 protein was

not concomitantly increased but was in fact somewhat
decreased in fat of these streptozotocin-treated animals
(fig. 23).
IRS-1 protein was not detectable in rat liver tissue
due to the presence of a nonspecific band of approximately
the same size as IRS-1.

This nonspecific protein was very

highly expressed in comparison to IRS-1, and the proximity
of this protein to IRS-1 on SOS-PAGE gels was so close that
its signal masked IRS-1 expression.

Substantial evidence

suggests that this band represents a nonspecific protein
interaction.

First, the band migrated slightly ahead of the

positive control, which normally lined up with IRS-1.
Secondly, IRS-1 is expressed at very low levels in all
tissues studied, and the expression of this band was much
too high to have been IRS-1.

Third, there was a faint band

that lined up with the positive control which was not
quantitatable due to the high expression of the nonspecific
band (data not shown).

Therefore, it is difficult to
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determine whether our data is in full agreement with the
work of Saad, et al.

(173), since fat was not a part of

their study, nor did they measure RNA levels in either
model.
IRS-1 expression has also been shown to be affected by
insulin levels at the level of protein stability (181-183).
IRS-1 is degraded in 3T3-Ll adipocytes pre-treated with high
insulin concentrations (1 µM) by an extra-lysosomal calciumdependent protease into two fragments of 79 and 90 kDa
(181,182).

Based on these studies, it would seem logical

that the hyperinsulinemia of KKAY mice would have an effect
on protein levels of IRS-1.

In contrast, there were no

observed differences between KKAY and C57 IRS-1 levels in
fat or liver (fig. 2).

One possible explanation for the

lack of an observed decrease in IRS-1 protein levels in
hyperinsulinemic KKAY mice is that the insulin levels of
these animals (500 µU/ml) only corresponds to an insulin
concentration of 3 nM, which may not be high enough to
elicit insulin-induced proteolysis of IRS-1.

One

dissimilarity between the present study and the prior
studies (181,182) is that we failed to achieve statistically
significant effects of insulin to lower IRS-1 protein levels
in 3T3-Ll cells pre-fed overnight with 2 µM insulin (fig.
17), although the mean values for IRS-1 protein in the
insulin-treated cells tended to be lower than control cells.
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Phosphorylation
As is shown in fig. 7 and fig. 10, the basal
phosphorylation of IRS-1 is not elevated in KJ<AY mice as
compared to control C57 mice.

This is different from the

high basal phosphorylation of the insulin receptor in these
animals (fig. 7 and fig. 8).

However, like the insulin

receptor, acute insulin treatment did not stimulate tyrosine
phosphorylation of IRS-1 in adipocytes from KKAY mice or KKAY
mice treated with pioglitazone.

This was not surprising,

since specific increases in insulin receptor tyrosine
autophosphorylation are required for subsequent IRS-1
phosphorylation (67,94,184-186).
The hyperglycemic and hyperinsulinemic condition
probably plays a role in the lack of IRS-1 phosphorylation
in insulin-stimulated KKAY adipocytes, since the 3T3-Ll
cells pre-fed with high insulin and high glucose were
likewise unresponsive (fig. 18).

Another study likewise

showed a decrease in the responsiveness of 3T3-Ll cells to
insulin-stimulated phosphorylation of IRS-1 after a 24 hr
incubation of the cells in 100 nM insulin (183).

Insulin

pre-treatment of the 3T3-Ll cells in both cases also led to
an increase in the basal tyrosine phosphorylation of IRS-1
(fig. 18).
Pioglitazone treatment of KKAY mice did not restore the
insulin-stimulated tyrosine phosphorylation of IRS-1 (fig. 7
and fig. 10).

As mentioned above, pioglitazone and
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troglitazone have both been shown to increase receptor
tyrosine kinase activity for autophosphorylation and
phosphorylation of synthetic substrates (16,42-44), although
there is one study by Zhang, et al. in which no effect of
pioglitazone treatment was seen on insulin-stimulated
phosphorylation of the insulin receptor or IRS-1 (48).
study by Zhang, et al. and another by Sizer, et al.

The

(47),

although done in nonphysiologic cell culture models, both
suggested a more direct effect of pioglitazone on PI3K
activity.

Therefore, it is possible that the increased

insulin sensitivity (20) and insulin-stimulated glucose
transport (18) in KKAY mice treated with pioglitazone may be
due to a more direct effect of pioglitazone further
downstream in the insulin-signaling pathway than IRS-1.

Siqnif icance of IRS-1 Function
It should be noted that expression of a nonfunctional
IRS-1 molecule in transgenic IRS-1 knockout mice resulted in
a decrease in both pre-and post-natal growth as well as
insulin resistance (109,110).

However, the viability of

these animals homozygous for disrupted IRS-1 suggests that
there are IRS-1-independent pathways in insulin signaling to
both mitogenic and metabolic effects.

In fact, in one of

these studies, Araki, et al. found that another IRS-like
molecule immunologically distinct from IRS-1 and slightly
larger was discovered to be tyrosine-phosphorylated by
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insulin stimulation {110).

It is therefore likely that

alterations observed in IRS-1 expression or phosphorylation,
while they may contribute to insulin resistance or lack of
insulin signaling to growth effects, may not be entirely
disruptive to cellular processes due to the existence of
alternate pathways of signaling from the insulin receptor
( 110) •
On the other hand, IRS-1 is a multisite docking
protein, binding to at least four different proteins on
insulin stimulation of the insulin receptor and consequent
tyrosine phosphorylation of IRS-1 {10,91,116-120).

These

four proteins, PI3K p85a, GRB2, Nck, and Syp, are thought to
branch insulin's signal to various cellular processes
{10,91).

Therefore, IRS-1 is probably a very important

molecule in insulin signaling even though there are likely
other substrates of the receptor as well.

One such

substrate, She, may actually be more important than IRS-1 in
insulin signaling through GRB2 {105,116,141-143,145) and
will be discussed in more detail below.

PI3K p85a

Expression
The expression of PI3K p85a was measured using a
monoclonal antibody directed against the SH2 domains of
p85a.

As seen in fig. 2, two major bands of approximately
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the same size are recognized by this antibody in fat tissue.
This may be due to cross-reactivity with another protein,
p87P, which has high homology to p85a (128).

While both

proteins may associate with the pllO subunit (128), we have
found that only the lower band (p85a) associates with IRS-1
on insulin stimulation of isolated adipocytes (fig. 11).

In

addition, the lower band was aligned with the baculovirusexpressed p85a positive control, while the upper band did
not.

Also, a recently available antibody specific for the

SH3 domains of p85a detected only the lower of the two bands
in fat tissue (data not shown).

For these reasons, the

lower band observed in fat tissue was quantitated as p85a.
PI3K p85a protein levels in liver of diabetic KKAY mice
were not significantly different from the levels in liver
tissue of nondiabetic control animals (fig. 2), and there
was no effect of pioglitazone treatment.

In contrast, p85a

protein levels were significantly decreased in epididymal
fat tissue of KKAY mice by 53% relative to the C57 p85a
levels (fig. 2).

The correction of p85a levels in KKAY fat

by pioglitazone treatment occurred in the absence of a
concordant increase in p85a mRNA, indicating that
pioglitazone treatment may increase p85a levels in adipose
by augmenting p85a translation or protein stability.
findings support two conclusions.

Such

First, the expression of

p85a in KKAY mice is regulated differently in fat than in
liver tissue.

Secondly, the action of pioglitazone on p85a
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expression appeared to be tissue-specific and posttranscriptional.
The decreased expression of p85a in KKAY fat does not
seem to be caused by the diabetic condition.

First, if the

decreased expression was due to the high circulating insulin
and glucose levels of the KKAY mice, one would expect to see
the same decreased expression in liver tissue as in the case
of the insulin receptor; however, this difference could be
explained by tissue-specific regulation.

Secondly, the

results from the 3T3-Ll cells indicated that high insulin
and glucose actually caused a near-significant increase
(p=0.052) in PI3K protein levels over the expression in
control cells (fig. 19).

Likewise, another group found a

slight increase in PI3K protein levels with a 24 hr
pretreatment of 3T3-Ll cells with high insulin alone (181).
Hyperglycemia in the absence of hyperinsulinemia showed
a tissue-specific effect in the opposite direction from that
observed in KKAY mice.

In epididymal fat from

streptozotocin-treated insulin-deficient rats, there was no
significant difference in p85a protein or RNA levels
relative to control (fig. 25).

In liver tissue, PI3K p85a

protein levels were 68.9 ± 12.7% higher than control (n=9,
p=0.0006).

Once again, there was not a similar increase in

p85a mRNA (fig. 26).

Although the tissue-specific increase

cannot be explained, one possibility is that p85a is
regulated in a tissue-specific manner by the hyperglycemic
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hypoinsulinemic condition itself.

This is quite plausible

owing to the differing glucose uptake properties of fat
verses liver.

Liver is more freely permeable to glucose due

to the higher Km of the GLUT2 glucose transporter compared
to fat tissue, which expresses the low Km GLUT4 (187).

As a

result, liver may be more susceptible to the effects of
hyperglycemia than fat.

Insulin-Stimulated Association with IRS-1
There is considerable evidence to suggest that PI3K
p85a associates with IRS-1 on insulin stimulation
(10,91,100-102,106,lll-113,115,119,l26,134-139).

As shown

in fig. 11, p85a was found in anti-IRS-1 immunoprecipitates
in the insulin-stimulated adipocytes from nondiabetic
control animals, but very little was found in the nonstimulated control cells.

However, the association of p85a

with IRS-1 was not stimulated by insulin in adipocytes
isolated from KKAY mice or KKAY mice treated with
pioglitazone (fig. 11, fig 12).

This finding is consistent

with the lack of insulin-stimulated tyrosine phosphorylation
of the insulin receptor and IRS-1 in adipocytes from these
groups (figs. 7, 8, and 10), since IRS-1 must be tyrosinephosphorylated to associate with the SH2 domains of PI3K
p85a (100,101,112,113).
The failure of KKAY adipocytes to show insulinstimulated phosphorylation of IRS-1 and recruitment of p85a
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to IRS-1 complexes has implications regarding sensitivity of
these cells to insulin.

The association of p85a to

phosphorylated IRS-1 activates the catalytic activity of the
pllO subunit of PI3K, an action related to insulin
stimulation of GLUT4 glucose transporter recruitment to the
plasma membrane and insulin-stimulated glucose uptake
(95,96,98,99,102,111).

In epididymal fat from KKAY mice,

the expression of GLUT4 was reported to be decreased
relative to control C57 mice (18).

In the present study,

the expression of p85a, the insulin-stimulated
phosphorylation of the receptor and IRS-1, and the
association of p85a with IRS-1 were all found to be lower
than normal.

These combined alterations in adipose tissue

likely contribute to the insulin resistance of these
animals, since glucose uptake through GLUT4 is the primary
mechanism by which insulin stimulates glucose transport into
these cells (188).

Other studies would suggest that a

defect in recruitment of GLUT4 to the plasma membrane is
more likely than a defect in expression of GLUT4 in NIDDM
(187), although the present data and past results from this
laboratory (18) suggest that both defects may exist in KKAY
mice.
One point that becomes apparent from the data in figs.
11 and 12 is that pioglitazone treatment did not increase
the amount of p85a in anti-IRS-1 immunoprecipitates of
insulin-stimulated isolated adipocytes, even though
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pioglitazone treatment corrected the levels of p85a in the
treated animals (fig. 2).

This result may indicate that the

correction of p85a levels by pioglitazone treatment as shown
in fig. 2 is unrelated to the correction of blood glucose
levels by pioglitazone.

However, Dailey, et al. found that

insulin-stimulated isolated abdominal adipocytes from
pioglitazone-treated KKAY mice showed an increased amount of
PI3K activity in anti-phosphotyrosine immunoprecipitates as
compared to non-treated KKAY adipocytes (189).
While these results seem contradictory to my findings,
there are several possible explanations for this difference.
First, Dailey et al. used anti-phosphotyrosine
immunoprecipitates, which are not necessarily the same as
anti-IRS-1 immunoprecipitates.

While IRS-1 needs to be

phosphorylated for the association with p85a to occur, the
anti-phosphotyrosine antibodies immunoprecipitate a plethora
of tyrosine-phosphorylated proteins.

It is possible, then,

that an anti-phosphotyrosine immunoprecipitation could
precipitate unidentified phosphotyrosine-containing proteins
other than IRS-1, which may also associate with p85a.

The

presence of an IRS-2 in IRS-1 knockout mice is an example of
a possible alternate substrate for the receptor (110).
There are several reports of p85a association with the
insulin receptor alone (190-192), although this is
controversial (115).

Also, there are reports documenting

138
insulin-stimulated tyrosine phosphorylation of p85a
{125,133).
Another difference is that Dailey et al. measured PI3K
activity, while fig. 11 demonstrates the amount of p85a
protein in the IRS-1 immunoprecipitates.

This difference

may mean that the activity measurement is more sensitive
than the measurement of the amount of protein in
immunoprecipitates, or possibly that pioglitazone acted to
increase the activity of the enzyme in the absence of an
association with IRS-1.
Finally, the PI3K activity data generated by Dailey, et

al. were obtained from abdominal rather than epididymal fat
{189).

The same study showed a higher responsiveness of

abdominal fat to insulin and pioglitazone as compared to
epididymal fat (189).

Therefore, the effect of pioglitazone

on insulin-stimulated PI3K association with IRS-1 may not be
detectable in epididymal fat to the same extent as
pioglitazone's effect on PI3K activity in abdominal fat.
One other study by Zhang, et al. showed results
corresponding to the data shown in fig. 6, as well as the
results of Dailey, et al.

Pioglitazone-treated Chinese

hamster ovary cells overexpressing the insulin receptor
showed an increase in the insulin-stimulated PI3K activity
in anti-phosphotyrosine immunoprecipitates as compared to
such activity in untreated cells.

At the same time, there

was not an increase in the tyrosine phosphorylation of the
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insulin receptor or IRS-1 (48).

There was also an increase

in the amount of PI3K p85a protein in anti-phosphotyrosine
immunoprecipitates in the pioglitazone-treated cells over
the control cells (48). Therefore, although the present
studies failed to detect an effect of pioglitazone treatment
on PI3K association with IRS-1 (fig. 11 and fig. 12),
pioglitazone may actually be acting at this level to
increase insulin sensitivity and insulin-stimulated glucose
uptake through GLUT4.
There is one additional report suggesting another
possible mechanism of pioglitazone action.

sizer, et al.

showed that pioglitazone treatment of 3T3-Ll cells prevented
isoproterenol-induced inhibition of insulin-stimulated PI3K
activity (47).

such results indicated that pioglitazone

inhibited a cAMP-dependent negative control mechanism, since
the drug also prevented the inhibition of PI3K activity by
cell-penetrating analogs of cAMP (47).

Therefore, it is

possible that pioglitazone may act at points other than
insulin receptor phosphorylation and association of IRS-1
with PI3K.

Proteins Elevated in KKAY Mice
While the levels of the insulin receptor and p85a were
found to be decreased in KKAY mice, the levels of GRB2, Nck,
and Syp were found to be elevated, as is shown in fig. 2.
Each of these proteins has been implicated in insulin
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signaling to growth-related effects (116,141,148,155,157,
161), as opposed to PI3K, which appears to have primarily a
metabolic role {95,96,99,102).

The difference in the levels

of these proteins as compared to control levels were all
more pronounced in epididymal fat tissue than liver,
although all three were found to be significantly higher in
KKAY liver than control.

Pioglitazone had little or no

effect on the expression of any of these proteins.

GRB2

Expression
As shown in fig. 3, the expression of GRB2 was more
than 3 times higher in KKAY fat than in the control animals,
and pioglitazone treatment did not alter these levels.

This

increased expression may be partially due to the
hyperinsulinemia and hyperglycemia of the animals because
overnight incubation of 3T3-Ll cells with high insulin and
high glucose caused a significant 35.7±8.1% increase
{p<0.05, n=22) in expression.

Although the change in

cultured cells was much smaller than the difference observed
in the animal model, such findings may imply that there is
an effect of these agents on the expression of this protein.
It is possible that the overnight incubation in high glucose
and high insulin is not long enough to replicate the chronic
condition of the diabetic animals, or that there are· other

141
factors involved in vivo that are absent in an in vitro
model.

Also, the streptozotocin-treated rats showed no

alteration in the expression of GRB2 in either fat or liver
(fig. 27 and fig. 28), suggesting that hyperglycemia alone
is probably not a factor leading to increased GRB2
expression.

Association with IRS-1 or She
The association of GRB2 with IRS-1 was not measurable
with the methodology used in the present study.

The studies

that have shown association of IRS-1 with GRB2 have been
done in cell systems constructed to overexpress the insulin
receptor, IRS-1, or GRB2 (91,105,116,120,148).

The physical

association of GRB2 with IRS-1 may not be as strong or as
abundant as the association of IRS-1 with p85a in vivo.
Another possible explanation for our ability to detect p85a
but not GRB2 in the anti-IRS-1 immunoprecipitates is the
time course used.

The time point used for insulin

stimulation of the isolated adipocytes (2 minutes) was
chosen because it was the time point at which maximal
insulin-stimulated phosphorylation of IRS-1 was achieved in
control cells (data not shown).

This time course also

seemed appropriate for measuring p85a association, since the
association with IRS-1 was measurable in the stimulated
control cells (fig. 11).

The stimulation of glucose

transport (18) appears to occur more rapidly than the
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stimulation of growth-related effects (104,145) by insulin,
and therefore a longer time point may be required for
detection of GRB2 in anti-IRS-1 immunoprecipitates.
Another reason that GRB2 may not be detectable in antiIRS-1 immunoprecipitates in this study is that GRB2 is found
to associate with another protein, She, to a much greater
extent than with IRS-1 (142).

Future studies should be

directed at measuring the regulation of She and its
association with GRB2 in this model, since the higher
expression of GRB2 in KKAY mouse fat was the largest
difference compared to C57 control mice observed in this
study.

Possible Downstream Effects of Increased GRB2 Expression
The elevated expression of GRB2 in KKAY mice has
several possible implications in cell signaling, presuming
that higher levels of this protein increased insulin
signaling through this pathway.

One possible explanation

for the increased GRB2 expression in these animals is that
this elevated expression is a compensatory mechanism brought
about by the diabetic condition.

First, evidence exists for

the association of dynamin with GRB2, and the subsequent
activation of the GTPase activity of dynamin by insulin
stimulation (140,154).

Dynamin function may be involved in

the pinching off of coated vesicles from the plasma membrane
for endocytosis, and it could thus be involved in receptor
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internalization (154).

If the high insulin levels in KKAY

mice do indeed cause an increase in insulin receptor
internalization and degradation, then more GRB2 may be
needed to meet the increased demands for receptor
internalization in these animals.

This theory is consistent

with the findings in 3T3-Ll adipocytes where high insulin
and high glucose caused an increase in GRB2 expression (fig.
20).

It is also consistent with the absence of a difference

in GRB2 levels between control and streptozotocin-treated
rats, since the insulin levels in streptozotocin-treated
rats are lowered (fig.27 and fig. 28).

One might even

expect a decrease in the expression of GRB2 in IDDM if this
were actually the case, unless a basal level is maintained
even in the absence of high insulin levels.
Another mechanism by which an increased GRB2 expression
may compensate for the diabetic condition involves the
expression of glucose transporters.

Adipose tissue contains

both GLUTl and GLUT4 glucose transporters, although GLUT4 is
the predominant species (21,187,188).

GLUTl is present in

many tissues, and is believed to be responsible for basal
glucose uptake (21,188), while GLUT4 is known to be the
transporter responsible for the majority of insulinstimulated glucose uptake in fat and muscle tissue
(21,95,187,188).

In prior studies, the expression of GLUT4

was shown to be significantly lower in epididymal fat from

KKAY mice as compared to control C57 mice, and KKAY mice were
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also nearly unresponsive to insulin stimulation of glucose
uptake {18).

Therefore, the lower levels of GLUT4 and PI3K

p85a (fig. 1) in adipose tissue could contribute to the
insulin resistance of KKAY mice, since both have been
implicated in insulin-stimulated glucose uptake {21,95,99,
102,187,188).

In contrast to this insulin-stimulated

pathway, the levels of GRB2 (fig. 2) and GLUTl (Bonini,
Dailey, Colca, White, and Hofmann, submitted for
publication, September 1994) in adipose tissue from this
model of insulin resistance were much higher than control
levels.

GRB2 binding to phosphorylated IRS-1 or She causes

it to bind to and activate the guanine nucleotide exchange
factor Sos, leading to activation of ras {116,141,144,148).
Activated ras binds to and activates raf-1, which then
phosphorylates MAP kinase kinase.

Overexpression of

constitutively active forms of either ras or raf-1 in 3T3-Ll
adipocytes has been shown to increase the expression and
activity of GLUTl, resulting in increased basal glucose
uptake {149-151).

Such findings were consistent with the

concordantly higher expression of GRB2 and GLUTl in KKAY
mice, as well as the higher basal glucose uptake measured in
adipocytes from these animals compared to those from
nondiabetic controls {18).
Further evidence for a role of GLUTl upregulation as a
compensatory response comes from studies in which 3T3-Ll
adipocytes were deprived of glucose for 24 hr.

This
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resulted in an increase in GLUTl expression and a decrease
in GLUT4 (193,194).

During glucose deprivation, GLUTl was

found primarily in the plasma membrane, and the increase in
GLUTl was attributed to an increase in the rate of synthesis
and stability of the protein.

One potential role for GLUTl

is to act as a stress response protein, and it is thought
that the upregulation of GLUTl in this condition was a
compensatory response to meet the glucose requirement of the
cells (188,194,195).

In the case of the KKAY mice, it is

thus possible that the elevated levels of GRB2 and GLUTl are
a compensatory response to the insulin resistance and the
lower levels of IR, PI3K p85a, and GLUT4 in these animals.
Although pioglitazone treatment did not significantly alter
the levels of GRB2 in KKAY epididymal fat, it increased IR,
p85a, and GLUT4 expression toward control levels, while
GLUTl protein levels were decreased to control levels by
pioglitazone treatment.
Finally, GRB2 signaling has also been related to the
growth and mitogenic effects of insulin (105,142,146).

An

increase in GRB2 may therefore route more of insulin's
signal in this direction, since GRB2 was found to be ratelimiting in insulin signal transduction to AP-1 and fos when
IRS-1 was overexpressed in CHO cells (142).

Therefore, a

disruption of the proper stoichiometries in insulin
signaling could alter the expression of other genes as well
( 14 2) •
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Nck

Expression
The expression of Nck, like GRB2, was higher in KKAY
mice as compared to control mice (fig. 3), although this
difference was not as large as that of GRB2.

The higher

expression was much more pronounced in adipose than in liver
tissue.

Also similar to the expression of GRB2 was the

effect of high glucose and high insulin in raising the
levels of Nck protein (fig. 20).

This observation may

indicate that these factors contribute to the higher
expression of Nck protein in KKAY mice.

Interestingly, Nck

protein levels were decreased significantly by 29.1±6.5%
(p=0.0123, n=9) in streptozotocin-treated rat liver, but not
in fat tissue (fig. 27 and fig. 28).

This result would

suggest that insulin may somehow regulate Nck expression, or
that other factors associated with hyperinsulinemia serve to
upregulate this protein in KKAY mouse liver as compared to
control animals.
Because the nature of this protein is not entirely
known, it is difficult to speculate on the possible
downstream effects of Nck overexpression in KKAY mice.
Nck has been shown to be a transforming oncogene when
overexpressed (157,196), and it may have a serine/threonine
kinase activity (156).

There is no data indicating that

KKAY mice have an increased incidence of tumor formation;
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however, there is some evidence suggesting that serine
phosphorylation of IRS-1 inhibits its insulin-stimulated
tyrosine phosphorylation (197), although there is no
evidence indicating that IRS-1 is a substrate for Nck.

It

remains possible that Nck could act as a negative regulator
of insulin-stimulated phosphorylation of IRS-1.

Association with IRS-1
As in the experiments with GRB2, Nck was not found in
IRS-1 immunoprecipitates at the time point used for the
detection of p85a.

Syp

Expression
The protein levels of Syp were also increased in
insulin-resistant KKAY fat and liver as compared to
nondiabetic control tissues (fig. 3).

Unlike GRB2 and Nck,

syp expression was not significantly altered in 3T3-Ll
adipocytes pre-fed with high insulin and high glucose (fig.
20).

As demonstrated with GRB2 and Nck, however, the

changes in expression observed with high insulin and high
glucose treatment of 3T3-Ll cells were not as great as those
seen in the animals, but it is possible that a longer
incubation in this medium might result in an increase
similar to that seen in the KKAY mice.
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By contrast, Syp expression was significantly decreased
in the insulin-deficient streptozotocin-treated diabetic
rats as compared to the control rats in both tissues
studied.

This result suggests that under some conditions

insulin levels may regulate the expression of Syp.

This

conclusion would be consistent with a catalytic role of Syp
as a protein tyrosine phosphatase with the insulin receptor
as a potential substrate (159).

The increased basal

phosphorylation of the insulin receptor in KKAY mice may
require a higher level of tyrosine phosphatases to
dephosphorylate the

~

subunit, which is required for

receptor recycling (198).

In the hypoinsulinemic state of

IDDM, the receptor is not phosphorylated and the demand for
syp to dephosphorylate it would be decreased.
In addition to a potential role for facilitating
receptor recycling, other actions for Syp have also been
suggested.

First, Syp has been shown to be a positive

mediator of insulin signaling to mitogenesis (161).

In rat-

1 fibroblasts stably expressing the insulin receptor,
insulin-stimulated DNA synthesis was inhibited by
microinjection of anti-Syp antibodies, phosphonopeptides
containing the IRS-1 phosphotyrosine binding sites for Syp
SH2 domains, or Syp SH2-GST fusion proteins by 60-90%, 5060%, and 90%, respectively (161).

Secondly, the insulin

receptor reportedly phosphorylated Syp in its SH2 domains,
thus inactivating it (159).

This suggests that in a·
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condition where the insulin receptor is activated, Syp would
be inactivated.

Therefore, the high basal phosphorylation

of the insulin receptor in KKAY mice could be altering Syp
function.

Association with IRS-1
As in the case of GRB2 and Nck, Syp was not detectable
in IRS-1 immunoprecipitates from the isolated adipocytes at
the time point studied.

As mentioned above, the association

of all three of these proteins with IRS-1 had been
discovered using systems where one or more of the components
(the receptor, IRS-1, GRB2, Nck, or Syp) were overexpressed,
or using systems with peptide sequences corresponding to
pYXXX sequences of IRS-1 or SH2 domains of the other
proteins.

Most, if not all of the work done concerning

these factors has been done in such systems.

Therefore,

although these associations are most likely real, they may
not be measurable when present at normal physiologic levels
in the in vivo system used in this study.
To complicate the matter, the immunoprecipitation
methodology results in including the immunoprecipitating
antibody in the final pellet.

When this pellet is disrupted

by adding Laemmli buffer and boiling, the IgG heavy and
light chains of the immunoprecipitating antibody become part
of the sample to be run on the gel.

The IgG heavy chain

migrates as 50 kDa (fig. 11), while the IgG light chain
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migrates as 25 kDa (data not shown).

Both chains cross-

react with the anti-mouse secondary antibody used for the
detection of the co-precipitating proteins.

Nck and GRB2

migrate as 44.2 and 25.7 kDa, respectively, and thus their
signals may be obscured by this cross reactivity of the
heavy and light IgG chains of the immunoprecipitating
antibody with the secondary immunoblotting antibody.

Significance of Alterations in Signaling Components

Alterations as Contributing Factors to the Development
of NIDDM
Because the pathophysiology of KKAY mice closely
resembles the symptoms of NIDDM in humans, several of the
alterations observed in KKAY mice may contribute to the
onset of NIDDM.

While the lower insulin receptor levels in

KKAY mice are most likely secondary to the hyperinsulinemia
of these animals, this certainly would contribute to insulin
resistance.

Insulin resistance of peripheral tissues would

result in elevated blood glucose levels, thus leading to
further increased insulin release.

High circulating insulin

would in turn decrease the number of receptors by
internalization and degradation.

Such a decrease in

receptor number would thus exacerbate the diabetic
condition.
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The receptor kinase defect measured in KKAY epididymal
adipocytes would similarly contribute to the development of
diabetes.

Increased glucose and insulin levels inhibit the

insulin receptor kinase (42,43,177,199-201).

Accordingly,

diminished receptor kinase activity would contribute to
insulin resistance, thus leading to further elevation of
blood glucose and circulating insulin levels (1).
Likewise, the inability of insulin to acutely stimulate
phosphorylation of IRS-1 and the subsequent association with
and activation of PI3K in these receptor-defective cells
would also decrease the sensitivity of the cells to insulin
due to the connection between PI3K activity and GLUT4
translocation and activation (95,96,99,102).

The decreased

amounts of PI3K p85a (fig. 2) and GLUT4 (18) in KKAY mice
would also exacerbate this condition.

The lowered

expression of p85a in KKAY mouse fat did not appear to be
due to the diabetic condition, and may thus be a
contributing factor to the initial resistance of adipose
tissue to insulin.
The increased expression of the other three proteins
could all potentially play a role in contributing to the
insulin resistant condition, especially if proper
stoichiometries of signaling components are required for
proper signaling (142).

In the case of KKAY mice, where

the stoichiometry of these early signaling components is
much different than in the normal C57 mice, proper signaling
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could be disrupted.

This could result in routing the

signals that enter the cell in inappropriate directions.

Alterations as Compensation for Insulin Resistance
The higher expression of GRB2 in adipose tissue of KKAY
mice over control levels was the most dramatic change seen
in this study.

As an early insulin signaling component

upstream of ras and MAP kinase, GRB2 has been implicated in
regulation of cell growth (105,142), mitogenesis (105,142),
gene expression (142), protein synthesis (44,116,144,202),
and glucose transport (116,144,149,151).

Therefore, an

alteration at this upstream level could have a profound
effect on many cellular processes.

As discussed above, it

is possible that GRB2 overexpression is a cellular
compensation for the insulin resistance of the cells in two
respects.

First, GRB2 overexpression could lead to

activation of ras, which could then result in increased
GLUTl expression and activation (149,151).

This could bring

glucose into the insulin resistant cells without GLUT4
recruitment, thus accommodating the elevated blood glucose
levels.

Secondly, the association of GRB2 with dynamin and

the role dynamin may play in receptor-mediated endocytosis
suggests that increased GRB2 expression could be an attempt
by the cell to turn off the insulin signal by increasing
endocytosis.

Alternatively, GRB2 may be upregulated as a

response to the increased demand for

internalization~

It
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would be interesting to measure the levels of GRB2 and
dynamin in tissues of diabetic patients.

Pioglitazone as an Antihyperglycemic Agent
Pioglitazone treatment had very little effect on the
proteins studied, with the exception of raising the levels
of p85a in KKAY fat to control levels and partially
correcting the receptor number.

Each of these corrections

were lessened in importance by studying the function of
these proteins.

The insulin receptor tyrosine kinase was

not significantly corrected, nor was the association of p85a
with IRS-1.

Therefore, it seems likely that pioglitazone

elicits its effects at points other than these early
signaling components.

However, there is evidence to suggest

that it may act on PI3K directly (47,48), in which case a
correction of p85a protein by pioglitazone may still be
functionally significant.

The inability to measure many

effects of pioglitazone at this level does not decrease its
clinical importance in any way, since the fact still remains
that pioglitazone is a potent antihyperglycemic agent which
also acts to lower blood insulin levels, triglycerides, and
hepatic glucose production (20).

The exact mechanism of

pioglitazone action remains to be elucidated.

However, as

mentioned in the above discussion, there are reports of
thiazolidinediones affecting receptor tyrosine kinase
activity (16,42-44), mRNA stability (40), PI3K activity
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(47,48), and expression of genes encoding GLUT4,
(18,41,203), lipoprotein lipase (203), glucose-6-phosphate
dehydrogenase {203), GLUT! (19,41,203), adipsin (41), ap2
(41), and phosphoenolpyruvate carboxykinase (19).

It is

quite possible that one or more of these effects could bring
about some of the others.
The clinical trials of another compound of this class,
troglitazone, have been very favorable.

Troglitazone

increased insulin sensitivity and glucose tolerance in obese
patients with either normal or impaired glucose tolerance
prior to the study (46).

Therefore, this class of insulin

sensitizers, the thiazolidinediones, could be used to treat
type II diabetes in the future (46).

Caveats of this study
As in any study of this kind, it is important to
remember that an animal model of diabetes is not exactly the
same as the actual disease in humans.

Therefore, although

KKAY mice display quite a few of the same symptoms as type
II diabetics {36,37), they are not diabetic humans.

Also,

NIDDM is most likely a polygenic disorder with different
defects in different populations of affected individuals, so
one model would not suffice to demonstrate the actions of a
drug or the sites of defects.

In addition, due to the

nature of the breeding required to produce KKAY mice, that
is, the crossing of an obese mouse with a glucose-intolerant
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one, there is no genetically related normal control with
which to compare them.

C57Bl/6J mice were used as control

mice because they have blood insulin and glucose levels
analogous to normal humans, and they respond well to insulin
(18,37).

However, these are two different strains of mice,

so even though insulin signaling components may be altered
in their expression in KKAY mice relative to C57 mice, they
may not necessarily be involved in the onset of the diabetic
condition.
The other two models used have their own limitations as
well.

While 3T3-Ll adipocytes pre-fed with high insulin and

high glucose may help to isolate the effects of these
factors on fat cells, this model is limited in that the
other factors involved in type II diabetes such as high
triglyceride levels (20,36,37) or TNFa (204) are not
present.

Streptozotocin-induced IDDM is also not a perfect

model due to the possible effects of streptozotocin on other
cell types expressing GLUT2.

If this compound were indeed

cytotoxic to liver or kidney cells (205), then
streptozotocin treatment could result in alterations in the
physiology of the animals which may not occur in IDDM.
Lastly, although this study has identified alterations
in the expression of some early signaling components in this
model of insulin resistant diabetes, many of these
alterations were found to be associated with the diabetic
condition itself.

It is quite possible that the alterations
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observed in this study are a result of one or more other
defects in downstream signaling or glucose metabolism.

Such

defects could cause insulin resistance, resulting in
hyperglycemia and hyperinsulinemia, which may in turn alter
the expression or function of the insulin receptor, IRS-1,
PI3K, GRB2, Nck, or Syp.

Therefore, although the above

results help to increase our understanding of type II
diabetes and insulin resistance, they must be interpreted
with the understanding that these are just pieces of a much
larger puzzle.

Summary and Conclusions
The purpose of this study was to determine if the
expression or function of early insulin signaling components
were altered in an animal model of NIDDM compared to
nondiabetic animals, and also to determine if the
antidiabetic agent pioglitazone corrected or compensated for
any of these defects.

The results of this study show that

the expression of the insulin receptor, PI3K p85a, GRB2,
Nck, and syp was indeed altered in obese diabetic KKAY mice
compared to control nondiabetic C57Bl/6J mice.

In addition,

the tyrosine kinase activity of the insulin receptor was
found to be defective in insulin-stimulated
autophosphorylation of the receptor

~-subunit

and

phosphorylation of IRS-1 in adipocytes isolated from KKAY
mice compared to control adipocytes.

As a consequence, PI3K
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p85a association with IRS-1 following acute insulin
stimulation was also impaired in KKAY adipocytes.

While the

altered expression of the insulin receptor, GRB2, and Nck
was most likely due to the hyperglycemic and
hyperinsulinemic condition of KKAY compared to nondiabetic
mice, the lower levels of p85a in fat tissue of KKAY mice
may not have been due to the high glucose and high insulin
levels in these animals.

Therefore, the lower expression of

PI3K p85a in KKAY fat may contribute to the onset of
diabetes in this model, while altered expression of the
insulin receptor, GRB2, Nck, and Syp may have resulted from
the diabetic condition.

Pioglitazone treatment of KKAY mice

had limited effects on the signaling components studied,
although administration of the drug fully corrected the
altered p85a levels in KKAY fat to control levels.

However,

the amount of p85a associated with IRS-1 in acutelystimulated adipocytes isolated from pioglitazone-treated
KKAY mice was not increased over that observed in adipocytes
from untreated KKAY mice.
The observed alterations in insulin signaling are
likely to be a result of the insulin resistant condition as
well as contributing factors to the development of overt
NIDDM.

Because there are many different pathways involved

in insulin signaling, insulin-sensitive cells in prediabetic animals may upregulate certain factors to
compensate for a defect elsewhere in signaling or
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metabolism, and this may explain the increased GRB2, Nck,
and Syp expression in cells with decreased insulin receptors
or PI3K p85a.

Such compensatory measures may delay the

onset of severe NIDDM until the altered stoichiometry of
signaling molecules can no longer make up for the deficit or
until the stoichiometry is altered in such a way as to
inhibit appropriate signaling.

While further work is needed

to determine if such compensatory mechanisms exist, this
study has identified several alterations associated with
insulin resistant diabetes in this animal model of NIDDM.
Hopefully, these results will contribute to our
understanding of diabetes mellitus and the development of a
more efficient treatment for such a prevalent disease.
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